WO2016057755A1 - Placenta-derived adherent cell exosomes and uses thereof - Google Patents

Placenta-derived adherent cell exosomes and uses thereof Download PDF

Info

Publication number
WO2016057755A1
WO2016057755A1 PCT/US2015/054629 US2015054629W WO2016057755A1 WO 2016057755 A1 WO2016057755 A1 WO 2016057755A1 US 2015054629 W US2015054629 W US 2015054629W WO 2016057755 A1 WO2016057755 A1 WO 2016057755A1
Authority
WO
WIPO (PCT)
Prior art keywords
placenta
derived adherent
exosomes
adherent cell
mir
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2015/054629
Other languages
English (en)
French (fr)
Inventor
Eric Law
Andrew MORSCHAUSER
Aleksandar Francki
Jennifer Paredes
Kathy E. Karasiewicz-Mendez
Allan REDUTA
Vladimir Jankovic
Ivana DJURETIC
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clarity Acquisition II LLC
Original Assignee
Anthrogenesis Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55653751&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2016057755(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to JP2017518955A priority Critical patent/JP2017536096A/ja
Application filed by Anthrogenesis Corp filed Critical Anthrogenesis Corp
Priority to CN202310711769.3A priority patent/CN116731958A/zh
Priority to CA2964114A priority patent/CA2964114A1/en
Priority to US15/517,438 priority patent/US20170252379A1/en
Priority to DK15849339.5T priority patent/DK3204022T3/da
Priority to AU2015330855A priority patent/AU2015330855A1/en
Priority to EP15849339.5A priority patent/EP3204022B1/en
Priority to CN201580054280.7A priority patent/CN107106615A/zh
Publication of WO2016057755A1 publication Critical patent/WO2016057755A1/en
Anticipated expiration legal-status Critical
Priority to US16/740,054 priority patent/US11173182B1/en
Priority to AU2021204332A priority patent/AU2021204332A1/en
Priority to US17/495,985 priority patent/US20220241347A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/02—Coculture with; Conditioned medium produced by embryonic cells
    • C12N2502/025—Coculture with; Conditioned medium produced by embryonic cells extra-embryonic cells, e.g. amniotic epithelium, placental cells, Wharton's jelly

Definitions

  • compositions of placenta-derived adherent cell exosomes relate to compositions of placenta-derived adherent cell exosomes and methods of making and using the same.
  • Exosomes are small, non-cellular bodies derived from living cells. Generally, exosomes are 50-150 nanometers (nm) in diameter and composed of a phospholipid bilayer derived from multivesicular bodies or the plasma membrane of eukaryotic cells. Exosomes may be round in shape but also can be "cup-shaped" bodies that are visually identifiable using electron microscopy and other imaging techniques. Exosomes do not contain an intact nucleus or the requisite cellular components to support the metabolic and/or molecular functions of a cell, but exosomes may contain proteins, nucleic acids, and other molecules, or can be decorated with surface proteins, which can aid in their detection and isolation.
  • exosomes can reflect the cell-type from which they are derived and can consist of molecular markers that reflect the functional state of the cells of origin. Exosomes hold promise as research tools and as a therapeutic modality, but there is a need in the art for new and useful exosomes.
  • compositions comprising exosomes produced by and/or derived from placental cells, e.g., placenta-derived adherent cells.
  • the exosomes provided herein are produced by placenta-derived adherent cells that have been cultured in vitro for, e.g., 1, 2, 3, 4, 5, 6 or more passages. In certain embodiments, the exosomes provided herein are collected from placenta-derived adherent cells that have been cultured in vitro for 1 passage. In other certain embodiment, the exosomes provided herein are collected from placenta-derived adherent cells that have been cultured in vitro for 2 passages. In other certain embodiment, the exosomes provided herein are collected from placenta-derived adherent cells that have been cultured in vitro for 3 passages.
  • the exosomes provided herein are collected from placenta-derived adherent cells that have been cultured in vitro for 4 passages. In other certain embodiment, the exosomes provided herein are collected from placenta-derived adherent cells that have been cultured in vitro for 5 passages. In a specific embodiment, the exosomes provided herein are collected from placenta-derived adherent cells that have been cultured in vitro for 6 passages. In other certain embodiment, the exosomes provided herein are collected from placenta-derived adherent cells that have been cultured in vitro for more than 6 passages. In certain embodiments, the exosomes provided herein are collected from placenta-derived adherent cells plated at passage 6, and collected ⁇ e.g., harvested) from culture supernatant at passage 7.
  • the placenta-derived adherent cell exosomes described herein comprise particular markers. Such markers can, for example, be useful in the identification of the exosomes and for distinguishing them from other exosomes, e.g., exosomes not derived from placenta-derived adherent cells. See Section 5.1.1.
  • the placenta-derived adherent cell exosomes provided herein comprise one, two, three, four, or more of CD9, CD 10, CD 13, CD29, CD44, CD49b, CD49c, CD55, CD59, CD63, CD73, CD81, CD82, CD90, CD98, CD105, CD141, CD142, CD151, CD164, CD295, and/or CD200, i.e., such exosomes are one or more of CD9 + , CD10 + , CD13 + , CD29 + , CD44 + , CD49b + , CD49c + , CD55 + , CD59 + , CD63 + , CD73 + , CD81 + , CD82 + , CD90 + , CD98 + , CD105 + , CD141 + , CD142 + , CD151 + , CD164 + , CD295 + , and/or CD200 + , e.g., as determinable by flow cytometry, for example,
  • the placenta-derived adherent cell exosomes provided herein can be identified based on the absence of certain markers.
  • the placenta-derived adherent cell exosomes provided herein lack one, two, three, four, or more of the following markers: CD3, CDl lb, CD14, CD19, CD33, CD192, HLA-A, HLA-B, HLA-C, HLA-DR, CD1 lc and/or CD34, i.e., such exosomes are one or more of CD3 " , CD1 lb “ , CD14 “ , CD19 “ , CD33 , CD192 " , HLA-A “ , HLA-B “ , HLA-C “ , HLA-DR " , CDl lc “ and/or CD34 " , e.g., as determinable by flow cytometry, for example, by FACS. . Determination of the presence or absence of such markers can be accomplished using methods known
  • the placenta-derived adherent cell exosomes described herein are CD55 + and CD10 + as determined, e.g., by flow cytometry, for example, by FACS.
  • the placenta-derived adherent cell exosomes described herein are CD10 + and CD55 + (as determined by, e.g., FACS) and additionally contain CD82, CD142, CD49c, and CD90 at a level higher than chorionic villi mesenchymal stem cell exosomes or pre- adipocyte mesenchymal stem cell exosomes ⁇ e.g., the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451).
  • the placenta-derived adherent cell exosomes described herein do not contain detectable levels of CD4, CD5, CD6, CD7, CD8, CD16, CD24, CD25, CD26, CD27, CD32, CD35, CD37, CD39, CD45, CD46, CD54, CD56, CD61, CD74, CD86, CD88, CD91, CD99, CD103, CD108, CD112, CD117, CD119, CD120a, CD123, CD126, CD130, CD134, CD138, CD140a, CD140b, CD144, CD146, CD147, CD152, CD163, CD183, CD184, CD 186, CD191, CD 194, CD 196, CDwl98, CD202b, CD220, CD221, CD235a, CD252, CD266, CD271, CD273, CD274, CD318, CD326, CD333, CD334, HLA-DP, HLA-DQ, HLA-G, IgD, IgM, NG2, PDGF
  • the placenta-derived adherent cell exosomes do not contain detectable levels of CD4. In certain embodiments, the placenta-derived adherent cell exosomes do not contain detectable levels of CD5. In certain embodiments, the placenta-derived adherent cell exosomes do not contain detectable levels of CD6. In certain embodiments, the placenta-derived adherent cell exosomes do not contain detectable levels of CD7. In certain embodiments, the placenta-derived adherent cell exosomes do not contain detectable levels of CD8. In certain embodiments, the placenta-derived adherent cell exosomes do not contain detectable levels of CD 16.
  • the placenta-derived adherent cell exosomes do not contain detectable levels of CD24. In certain embodiments, the placenta-derived adherent cell exosomes do not contain detectable levels of CD25. In certain embodiments, the placenta-derived adherent cell exosomes do not contain detectable levels of CD26. In certain embodiments, the placenta- derived adherent cell exosomes do not contain detectable levels of CD27. In certain
  • the placenta-derived adherent cell exosomes do not contain detectable levels of CD32. In certain embodiments, the placenta-derived adherent cell exosomes do not contain detectable levels of CD35. In certain embodiments, the placenta-derived adherent cell exosomes do not contain detectable levels of CD37. In certain embodiments, the placenta-derived adherent cell exosomes do not contain detectable levels of CD39. In certain embodiments, the placenta- derived adherent cell exosomes do not contain detectable levels of CD45. In certain
  • the placenta-derived adherent cell exosomes do not contain detectable levels of CD46. In certain embodiments, the placenta-derived adherent cell exosomes do not contain detectable levels of CD54. In certain embodiments, the placenta-derived adherent cell exosomes do not contain detectable levels of CD56. In certain embodiments, the placenta-derived adherent cell exosomes do not contain detectable levels of CD61. In certain embodiments, the placenta- derived adherent cell exosomes do not contain detectable levels of CD74. In certain embodiments, CD46. In certain embodiments, the placenta-derived adherent cell exosomes do not contain detectable levels of CD54. In certain embodiments, the placenta-derived adherent cell exosomes do not contain detectable levels of CD56. In certain embodiments, the placenta-derived adherent cell exosomes do not contain detectable levels of CD61. In certain embodiments, the placenta
  • the placenta-derived adherent cell exosomes do not contain detectable levels of CD86. In certain embodiments, the placenta-derived adherent cell exosomes do not contain detectable levels of CD88. In certain embodiments, the placenta-derived adherent cell exosomes do not contain detectable levels of CD91. In certain embodiments, the placenta-derived adherent cell exosomes do not contain detectable levels of CD99. In certain embodiments, the placenta- derived adherent cell exosomes do not contain detectable levels of CD 103. In certain embodiments, CD86. In certain embodiments, the placenta-derived adherent cell exosomes do not contain detectable levels of CD88. In certain embodiments, the placenta-derived adherent cell exosomes do not contain detectable levels of CD91. In certain embodiments, the placenta-derived adherent cell exosomes do not contain detectable levels of CD99. In certain embodiments, the placent
  • the placenta-derived adherent cell exosomes do not contain detectable levels of CD 108. In certain embodiments, the placenta-derived adherent cell exosomes do not contain detectable levels of CD112. In certain embodiments, the placenta-derived adherent cell exosomes do not contain detectable levels of CD117. In certain embodiments, the placenta- derived adherent cell exosomes do not contain detectable levels of CD119, In certain
  • the placenta-derived adherent cell exosomes do not contain detectable levels of CD 120a. In certain embodiments, the placenta-derived adherent cell exosomes do not contain detectable levels of CD 123. In certain embodiments, the placenta-derived adherent cell exosomes do not contain detectable levels of CD 126. In certain embodiments, the placenta- derived adherent cell exosomes do not contain detectable levels of CD 130. In certain
  • the placenta-derived adherent cell exosomes do not contain detectable levels of CD 134. In certain embodiments, the placenta-derived adherent cell exosomes do not contain detectable levels of CD 138. In certain embodiments, the placenta-derived adherent cell exosomes do not contain detectable levels of CD 140a. In certain embodiments, the placenta- derived adherent cell exosomes do not contain detectable levels of CD 140b. In certain embodiments, the placenta-derived adherent cell exosomes do not contain detectable levels of CD 144. In certain embodiments, the placenta-derived adherent cell exosomes do not contain detectable levels of CD 146.
  • the placenta-derived adherent cell exosomes do not contain detectable levels of CD 147. In certain embodiments, the placenta- derived adherent cell exosomes do not contain detectable levels of CD 152. In certain embodiments, the placenta-derived adherent cell exosomes do not contain detectable levels of CD 163. In certain embodiments, the placenta-derived adherent cell exosomes do not contain detectable levels of CD 183. In certain embodiments, the placenta-derived adherent cell exosomes do not contain detectable levels of CD 184. In certain embodiments, the placenta- derived adherent cell exosomes do not contain detectable levels of CD 186.
  • the placenta-derived adherent cell exosomes do not contain detectable levels of CD 191. In certain embodiments, the placenta-derived adherent cell exosomes do not contain detectable levels of CD 194. In certain embodiments, the placenta-derived adherent cell exosomes do not contain detectable levels of CD 196. In certain embodiments, the placenta- derived adherent cell exosomes do not contain detectable levels of CDwl98. In certain embodiments, the placenta-derived adherent cell exosomes do not contain detectable levels of CD202b. In certain embodiments, the placenta-derived adherent cell exosomes do not contain detectable levels of CD220.
  • the placenta-derived adherent cell exosomes do not contain detectable levels of CD221. In certain embodiments, the placenta- derived adherent cell exosomes do not contain detectable levels of CD235a. In certain embodiments, the placenta-derived adherent cell exosomes do not contain detectable levels of CD252. In certain embodiments, the placenta-derived adherent cell exosomes do not contain detectable levels of CD266. In certain embodiments, the placenta-derived adherent cell exosomes do not contain detectable levels of CD271. In certain embodiments, the placenta- derived adherent cell exosomes do not contain detectable levels of CD273.
  • the placenta-derived adherent cell exosomes do not contain detectable levels of CD274. In certain embodiments, the placenta-derived adherent cell exosomes do not contain detectable levels of CD318. In certain embodiments, the placenta-derived adherent cell exosomes do not contain detectable levels of CD326. In certain embodiments, the placenta- derived adherent cell exosomes do not contain detectable levels of CD333. In certain embodiments, the placenta-derived adherent cell exosomes do not contain detectable levels of CD334. In certain embodiments, the placenta-derived adherent cell exosomes do not contain detectable levels of HLA-DP.
  • the placenta-derived adherent cell exosomes do not contain detectable levels of HLA-DQ. In certain embodiments, the placenta- derived adherent cell exosomes do not contain detectable levels of HLA-G. In certain embodiments, the placenta-derived adherent cell exosomes do not contain detectable levels of HLA-G. In certain embodiments, the placenta-derived adherent cell exosomes do not contain detectable levels of HLA-DQ. In certain embodiments, the placenta- derived adherent cell exosomes do not contain detectable levels of HLA-G. In certain
  • the placenta-derived adherent cell exosomes do not contain detectable levels of IgD. In certain embodiments, the placenta-derived adherent cell exosomes do not contain detectable levels of IgM. In certain embodiments, the placenta-derived adherent cell exosomes do not contain detectable levels of NG2. In certain embodiments, the placenta-derived adherent cell exosomes do not contain detectable levels of PDGF. In certain embodiments, the placenta- derived adherent cell exosomes do not contain detectable levels of SSEA-3.
  • the placenta-derived adherent cell exosomes described herein are CD82 + and contain a low level of CD 141 (i.e., are CD 141 (low)) as determined, e.g., by flow cytometry, for example, by FACS.
  • the placenta-derived adherent cell exosomes described herein comprise one or more markers at a level at least two-fold higher than the level of the marker as present in an equivalent number, or an equivalent mass, of exosomes derived from chorionic villi mesenchymal stem cells or pre-adipocyte mesenchymal stem cells as determinable by, e.g., FACS.
  • the placenta-derived adherent cell exosomes described herein comprise CD49c, CD 142, CD90, and/or CD82 at a level at least two-fold higher than the level of each marker, respectively, as present in exosomes derived from chorionic villi mesenchymal stem cells or pre-adipocyte mesenchymal stem cells, e.g., as determinable by flow cytometry, for example, by FACS.
  • the placenta-derived adherent cell exosomes described herein comprise a higher amount of CD49c, CD82, CD90, and/or CD 142 than the amount of said marker(s) in a non placenta-derived adherent cell exosome.
  • the placenta-derived adherent cell exosomes described herein comprise a higher amount of CD49c, CD82, CD90, and/or CD 142 than the amount of said marker(s) that is present in exosomes derived from chorionic villi mesenchymal stem cells (e.g., the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451).
  • chorionic villi mesenchymal stem cells e.g., the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451.
  • the placenta-derived adherent cell exosomes described herein comprise a higher amount of CD49c, CD73, CD82, CD90, and/or CD 142 than the amount of said marker(s) that is present in exosomes derived from pre-adipocyte mesenchymal stem cells.
  • the placenta-derived adherent cell exosomes described herein comprise one or more markers at a level at least two-fold lower than the level of the marker as present in an equivalent number, or an equivalent mass, of exosomes derived from chorionic villi mesenchymal stem cells or pre-adipocyte mesenchymal stem cells as determinable by, e.g., FACS.
  • the placenta-derived adherent cell exosomes described herein comprise a lower amount of CD 164 than the amount of said marker(s) in a non placenta-derived adherent cell exosome.
  • the placenta-derived adherent cell exosomes described herein comprise a lower amount of CD 164 than the amount of said marker(s) that is present in exosomes derived from pre-adipocyte mesenchymal stem cells or chorionic villi mesenchymal stem cells (e.g., the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451).
  • the placenta-derived adherent cell exosomes described herein comprise one or more nucleic acids.
  • said nucleic acids are non-coding RNAs.
  • said non-coding RNAs are microRNAs (miRNAs).
  • the placenta-derived adherent cell exosomes described herein comprise one or more miRNAs selected from the group consisting of: miR-218-5p, miR-133b, miR-422a, miR- 564, miR-16-5p, let-7a, miR-92, miR-142-3p, miR-451, miR-124-5p, miR-223-3p, miR-630, miR-296-5p, let-7b-3p and let-7d-3p.
  • the placenta-derived adherent cell exosomes comprise an miRNA that is miR-218-5p.
  • the placenta- derived adherent cell exosomes comprise an miRNA that is miR-133b. In a certain embodiment, the placenta-derived adherent cell exosomes comprise an miRNA that is miR-422a. In a certain embodiment, the placenta-derived adherent cell exosomes comprise an miRNA that is miR-564, miR-16-5p. In a certain embodiment, the placenta-derived adherent cell exosomes comprise an miRNA that is let-7a. In a certain embodiment, the placenta-derived adherent cell exosomes comprise an miRNA that is miR-92.
  • the placenta-derived adherent cell exosomes comprise an miRNA that is miR-142-3p. In a certain embodiment, the placenta- derived adherent cell exosomes comprise an miRNA that is miR-451. In a certain embodiment, the placenta-derived adherent cell exosomes comprise an miRNA that is miR-124-5p. In a certain embodiment, the placenta-derived adherent cell exosomes comprise an miRNA that is miR-223-3p. In a certain embodiment, the placenta-derived adherent cell exosomes comprise an miR A that is miR-630.
  • the placenta-derived adherent cell exosomes comprise an miRNA that is miR-296-5p. In a certain embodiment, the placenta-derived adherent cell exosomes comprise an miRNA that is let-7b-3p. In a certain embodiment, the placenta- derived adherent cell exosomes comprise an miRNA that is let-7d-3p. In another specific embodiment, the placenta-derived adherent cell exosomes comprise one or more of miRNAs miR-218-5p, miR-133b, miR-422a, and/or miR-564.
  • the placenta-derived adherent cell exosomes comprise one or more of miRNAs miR-133b, miR- 422a, miR-16-5p, miR-92, miR-142-3p, miR-451 , miR-223-3p, miR-296-5p, and/or miR-Let- 7d*/Let-7d-3p.
  • the placenta-derived adherent cell exosomes comprise one or more of miRNAs miR-591 , miR-218-5p, miR-133b, miR-422a, and/or miR-564.
  • said one or more miRNAs are present at a level at least two-fold higher than the level of the corresponding miRNA as present in chorionic villi mesenchymal stem cells.
  • the placenta-derived adherent cell exosomes when subjected to RT-PCR with respect to a specific miRNA and compared to a control RNA (e.g., RNU44), are contained at a level 1.1 , 2, 5, 10, 100, 500, 600, 700, 800, 900, 1000, 1 100 or 1200 times higher than the same miRNA in chorionic villi mesenchymal stem cell exosomes, or between 1.1 and 2, 2 and 5, 2 and 10, 5 and 10, 10 and 100, 100 and 500, 500 and 600, 600 and 700, 700 and 800, 800 and 900, 900 and 1000, 1000 and 1 100, or 1 100 and 1200 times higher than the same miRNA in chorionic villi mesenchymal stem cell exosomes.
  • the placenta-derived adherent cell exosomes comprise at least one marker at a level at least 1.1 times higher than exosomes derived from mesenchymal stem cells. In a certain embodiment, the placenta-derived adherent cell exosomes comprise at least one marker at a level at least 2 times higher than exosomes derived from mesenchymal stem cells. In a certain embodiment, the placenta-derived adherent cell exosomes comprise at least one marker at a level at least 5 times higher than exosomes derived from mesenchymal stem cells.
  • the placenta-derived adherent cell exosomes comprise at least one marker at a level at least 10 times higher than exosomes derived from mesenchymal stem cells. In a certain embodiment, the placenta-derived adherent cell exosomes comprise at least one marker at a level at least 100 times higher than exosomes derived from mesenchymal stem cells. In a certain embodiment, the placenta-derived adherent cell exosomes comprise at least one marker at a level at least 500 times higher than exosomes derived from mesenchymal stem cells.
  • the placenta-derived adherent cell exosomes comprise at least one marker at a level at least 600 times higher than exosomes derived from mesenchymal stem cells. In a certain embodiment, the placenta-derived adherent cell exosomes comprise at least one marker at a level at least 700 times higher than exosomes derived from mesenchymal stem cells. In a certain embodiment, the placenta-derived adherent cell exosomes comprise at least one marker at a level at least 800 times higher than exosomes derived from mesenchymal stem cells.
  • the placenta-derived adherent cell exosomes comprise at least one marker at a level at least 900 times higher than exosomes derived from mesenchymal stem cells. In a certain embodiment, the placenta-derived adherent cell exosomes comprise at least one marker at a level at least 1000 times higher than exosomes derived from mesenchymal stem cells. In a certain embodiment, the placenta-derived adherent cell exosomes comprise at least one marker at a level at least 1100 times higher than exosomes derived from mesenchymal stem cells. In a certain embodiment, the placenta-derived adherent cell exosomes comprise at least one marker at a level at least 1200 times higher than exosomes derived from mesenchymal stem cells.
  • the placenta-derived adherent cell exosomes described herein contain one or more angiogenic proteins selected from the group of Endoglin, Leptin,
  • Angiopoietin-2 G-CSF, Follistatin, FGF-2, HGF, VEGF-A, IL-8 and/or EGF.
  • populations of exosomes comprising the placenta-derived adherent cell exosomes described herein.
  • the populations of exosomes provided herein are pure or substantially pure with respect to their content of placenta-derived adherent cell exosomes, e.g., the populations of exosomes comprise about 90%, 95%, 98%>, 99%>, or 100% placenta-derived adherent cell exosomes.
  • the populations of exosomes provided herein comprise the placenta-derived adherent cell exosomes provided herein and one or more other types of exosomes, e.g., exosomes derived from a cell other than a placenta-derived adherent cell.
  • a population of placenta-derived adherent cell exosomes wherein about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%o, 99%), or 100% of the exosomes in said population are one or more of CD9 + , CD10 + , CD13 + , CD29 + , CD44 + , CD49b + , CD49c + , CD55 + , CD59 + , CD63 + , CD73 + , CD81 + , CD82 + , CD90 + , CD98 + , CD105 + , CD141 + , CD142 + , CD151 + , CD164 + , CD295 + , and/or CD200 + , as determinable by, e.g., FACS.
  • the placenta-derived adherent cell exosomes described herein may be isolated by any method known in the art suitable for the isolation of exosomes. See Section 5.2.
  • the placenta-derived adherent cell exosomes described herein can be isolated by centrifugation (e.g., density-dependent ultracentrifugation), polymer co-precipitation (e.g., ExoQuick-TC exosome precipitation reagent by System Biosciences), filtration (e.g., high-performance liquid chromatography and gel-filtration chromatography), antibody capture, or fluorescence-activated cell sorting (FACS).
  • the isolation and purification of the placenta- derived adherent cell exosomes provided herein results in a substantially pure placenta-derived adherent cell exosome population, e.g. , a placenta-derived adherent cell exosome population that is at least 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, or 90% pure, e.g., as determined by the presence of one or more markers associated with the placenta-derived adherent cell exosomes provided herein (e.g., surface markers and/or miRNAs).
  • the placenta-derived adherent cell exosome population that is at least 99% pure.
  • the placenta-derived adherent cell exosome population that is at least 98% pure. In a certain embodiment, the placenta-derived adherent cell exosome population that is at least 97% pure. In a certain embodiment, the placenta-derived adherent cell exosome population that is at least 96% pure. In a certain embodiment, the placenta-derived adherent cell exosome population that is at least 95% pure. In a certain embodiment, the placenta-derived adherent cell exosome population that is at least 94% pure. In a certain embodiment, the placenta-derived adherent cell exosome population that is at least 93% pure.
  • the placenta-derived adherent cell exosome population that is at least 92% pure. In a certain embodiment, the placenta-derived adherent cell exosome population that is at least 91% pure. In a certain embodiment, the placenta-derived adherent cell exosome population that is at least 90% pure.
  • compositions comprising placenta-derived adherent cell exosomes.
  • Such compositions generally do not comprise placental cells from which the placenta-derived adherent cell exosomes have been derived.
  • such compositions generally do not comprise cell culture supernatant from the cell culture from which the placenta- derived adherent cell exosomes have been derived.
  • purified placenta-derived adherent cell exosomes are formulated into pharmaceutical compositions suitable for administration to a subject in need thereof.
  • said subject is a human.
  • the placenta-derived adherent cell exosome-containing pharmaceutical compositions provided herein can be formulated to be administered locally, systemically subcutaneously, parenterally, intravenously, intramuscularly, topically, orally, intradermally, transdermally, or intranasally to a subject in need thereof.
  • the placenta-derived adherent cell exosome-containing pharmaceutical compositions provided herein are formulated for local administration.
  • the placenta-derived adherent cell exosome-containing pharmaceutical compositions provided herein are formulated for systemic subcutaneous administration. In a certain embodiment, the placenta-derived adherent cell exosome-containing pharmaceutical compositions provided herein are formulated for parenteral administration. In a certain embodiment, the placenta-derived adherent cell exosome-containing pharmaceutical compositions provided herein are formulated for intramuscular administration. In a certain embodiment, the placenta-derived adherent cell exosome-containing pharmaceutical compositions provided herein are formulated for topical administration. In a certain embodiment, the placenta-derived adherent cell exosome-containing pharmaceutical compositions provided herein are formulated for oral administration. In a certain embodiment, the placenta-derived adherent cell exosome-containing pharmaceutical
  • compositions provided herein are formulated for intradermal administration.
  • compositions provided herein are formulated for transdermal administration.
  • compositions provided herein are formulated for intranasal administration.
  • compositions provided herein are formulated for intravenous administration.
  • the placenta-derived adherent cells from which the exosomes provided herein are derived are CD34 , CD 10 , CD 105 and CD200 .
  • the placenta-derived adherent cells from which the exosomes provided herein are derived express one or more genes at a level at least two-fold higher than bone marrow-derived mesenchymal stem cells, wherein said one or more genes are one or more of: ACTG2, ADARB1, AMIG02, ARTS-1, B4GALT6, BCHE, Cl lorf9, CD200, COL4A1, COL4A2, CPA4, DMD, DSC3, DSG2, ELOVL2, F2RL1, FIJ10781, GATA6, GPR126, GPRC5B, HLA-G, ICAM1, IER3, IGFBP7, ILIA, IL6, IL18, KRT18, KRT8, LIPG, LRAP, MATN2, MEST, NFE
  • the placenta-derived adherent cells from which the exosomes provided herein are derived express one or more genes at a level at least two-fold higher than bone marrow-derived mesenchymal stem cells, wherein said one or more genes are one or more of LOVL2, ST3GAL6, ST6GALNAC5, and/or SLC12A8.
  • the placenta-derived adherent cells from which the exosomes provided herein are derived express one or more genes at a level at least two-fold higher than bone marrow-derived mesenchymal stem cells, wherein said one or more genes are one or more of CPA4, TCF21 , VTN, B4GALT6, FLJ10781 , and/or NUAK1.
  • the placenta-derived adherent cell exosomes described herein are isolated from placenta-derived adherent cell cultures that contain serum (e.g., fetal bovine serum). In certain embodiments, the placenta-derived adherent cell exosomes described herein are isolated from placenta-derived adherent cell cultures that lack serum.
  • serum e.g., fetal bovine serum
  • the placenta-derived adherent cells from which the placenta- derived adherent cell exosomes described herein are isolated have been passaged at least 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, or 20 times, or more, before said exosomes are isolated.
  • the placenta- -derived adherent ce lis have been passaged at least 1 time.
  • the placenta- -derived adherent ce lis have been passaged at least 2 times.
  • the placenta- -derived adherent ce lis have been passaged at least 3 times.
  • the placenta- -derived adherent ce lis have been passaged at least 4 times. In a certain embodiment, the placenta- -derived adherent ce lis have been passaged at least 5 times. In a certain embodiment, the placenta- -derived adherent ce lis have been passaged at least 6 times. In a certain embodiment, the placenta- -derived adherent ce lis have been passaged at least 7 times. In a certain embodiment, the placenta- -derived adherent ce lis have been passaged at least 8 times. In a certain embodiment, the placenta- -derived adherent ce lis have been passaged at least 9 times.
  • the placenta- -derived adherent ce lis have been passaged at least 10 times. In a certain embodiment, the placenta-derived adherent cells have been passaged at least 12 times. In a certain embodiment, the placenta-derived adherent cells have been passaged at least 14 times. In a certain embodiment, the placenta-derived adherent cells have been passaged at least 16 times. In a certain embodiment, the placenta-derived adherent cells have been passaged at least 18 times. In a certain embodiment, the placenta-derived adherent cells have been passaged at least 20 times.
  • the placenta-derived adherent cells from which the placenta-derived adherent cell exosomes described herein are isolated have been expanded for 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38 or 40 population doublings, or more, before said exosomes are isolated.
  • the placenta- derived adherent cells have been expanded for 1 population doubling.
  • the placenta-derived adherent cells have been expanded for 2 population doublings.
  • the placenta-derived adherent cells have been expanded for 3 population doublings.
  • the placenta-derived adherent cells have been expanded for 4 population doublings. In a certain embodiment, the placenta-derived adherent cells have been expanded for 5 population doublings. In a certain embodiment, the placenta-derived adherent cells have been expanded for 6 population doublings. In a certain embodiment, the placenta-derived adherent cells have been expanded for 7 population doublings. In a certain embodiment, the placenta-derived adherent cells have been expanded for 8 population doublings. In a certain embodiment, the placenta-derived adherent cells have been expanded for 9 population doublings. In a certain embodiment, the placenta-derived adherent cells have been expanded for 10 population doublings.
  • the placenta-derived adherent cells have been expanded for 12 population doublings. In a certain embodiment, the placenta-derived adherent cells have been expanded for 14 population doublings. In a certain embodiment, the placenta- derived adherent cells have been expanded for 16 population doublings. In a certain embodiment
  • the placenta-derived adherent cells have been expanded for 18 population doublings. In a certain embodiment, the placenta-derived adherent cells have been expanded for 20 population doublings. In a certain embodiment, the placenta-derived adherent cells have been expanded for 22 population doublings. In a certain embodiment, the placenta-derived adherent cells have been expanded for 24 population doublings. In a certain embodiment, the placenta- derived adherent cells have been expanded for 26 population doublings. In a certain
  • the placenta-derived adherent cells have been expanded for 28 population doublings. In a certain embodiment, the placenta-derived adherent cells have been expanded for 30 population doublings. In a certain embodiment, the placenta-derived adherent cells have been expanded for 32 population doublings. In a certain embodiment, the placenta-derived adherent cells have been expanded for 34 population doublings. In a certain embodiment, the placenta- derived adherent cells have been expanded for 36 population doublings. In a certain
  • the placenta-derived adherent cells have been expanded for 38 population doublings. In a certain embodiment, the placenta-derived adherent cells have been expanded for 40 population doublings.
  • the placenta-derived adherent cells from which the placenta- derived adherent cell exosomes described herein are isolated are at least 80%, at least 90%>, at least 95%, at least 99%, or 100% fetal in origin.
  • the placenta-derived adherent cells are at least 80% fetal in origin.
  • the placenta-derived adherent cells are at least 90% fetal in origin.
  • the placenta-derived adherent cells are at least 95% fetal in origin.
  • the placenta-derived adherent cells are at least 99% fetal in origin.
  • the placenta-derived adherent cells are at least 100% fetal in origin.
  • placenta-derived adherent cell exosomes and/or pharmaceutical compositions comprising placenta-derived adherent cell exosomes described herein. See Section 5.4.
  • the placenta-derived adherent cell exosomes and/or pharmaceutical compositions comprising placenta-derived adherent cell exosomes described herein are used to treat and/or prevent diseases and/or conditions in a subject in need thereof.
  • the placenta-derived adherent cell exosomes and/or pharmaceutical compositions comprising placenta-derived adherent cell exosomes described herein are used to promote angiogenesis and/or vascularization in a subject in need thereof.
  • placenta-derived adherent cell exosomes and/or pharmaceutical compositions comprising placenta-derived adherent cell exosomes described herein are used to modulate immune activity (e.g. , increase an immune response or decrease an immune response) in a subject in need thereof.
  • the placenta-derived adherent cell exosomes and/or pharmaceutical compositions comprising placenta-derived adherent cell exosomes described herein are used to repair tissue damage, e.g. , tissue damage caused by an acute or chronic injury, in a subject in need thereof.
  • the derived adherent cell exosomes and/or pharmaceutical compositions comprising placenta-derived adherent cell exosomes described herein are for use in a method for treating and/or preventing diseases and/or conditions in a subject in need thereof.
  • the pharmaceutical compositions comprising placenta-derived adherent cell exosomes described herein are for use in a method for treating diseases and/or conditions in a subject in need thereof.
  • the pharmaceutical compositions comprising placenta-derived adherent cell exosomes described herein are for use in a method for preventing diseases and/or conditions in a subject in need thereof.
  • the pharmaceutical compositions comprising placenta-derived adherent cell exosomes described herein are for use in a method for promoting angiogenesis and/or vascularization in a subject in need thereof.
  • the pharmaceutical compositions comprising placenta-derived adherent cell exosomes described herein are for use in a method for modulating immune activity (e.g. , increase an immune response or decrease an immune response) in a subject in need thereof.
  • the pharmaceutical compositions comprising placenta-derived adherent cell exosomes described herein are for use in a method for repairing tissue damage, e.g., tissue damage caused by an acute or chronic injury, in a subject in need thereof.
  • placenta-derived adherent cell exosomes and/or pharmaceutical compositions comprising placenta-derived adherent cell exosomes described herein are used as cytoprotective agents.
  • the placenta-derived adherent cell exosomes and/or pharmaceutical compositions comprising placenta-derived adherent cell exosomes described herein are provided in the form of a kit suitable for pharmaceutical use. See Section 5.5.
  • a method comprises incubating a placenta-derived adherent cell exosome and an exogenous agent, e.g. , pharmaceutical agent, for example incubating at room temperature, with or without saponin permeabilization, freeze/thaw cycles, sonication, or extrusion.
  • the exogenous agent e.g. , pharmaceutical agent
  • the exogenous agent is loaded into the placenta- derived adherent cell exosome by incubation at room temperature.
  • incubation e.g., incubation at room temperature
  • incubation is performed without saponin permeabilization of the exosome.
  • incubation e.g., incubation at room temperature
  • the exogenous agent e.g., pharmaceutical agent
  • the exogenous agent is loaded into the exosome by freeze/thaw cycles, for example, 1, 2, 3, 4, 5, or more freeze/thaw cycles.
  • the exogenous agent, e.g., pharmaceutical agent is loaded into the placenta- derived adherent cell exosome by sonication.
  • the exogenous agent e.g. , pharmaceutical agent
  • the exogenous agent is loaded into the placenta-derived adherent cell exosome by extrusion.
  • the exogenous agent is loaded into the placenta-derived adherent cell exosome by electroporation.
  • methods of loading placenta-derived adherent cell exosomes with exogenous agents, for example, pharmaceutical agents comprise any combination of the above.
  • the exogenous agent, e.g., pharmaceutical agent, loaded into the placenta-derived adherent cell exosomes described herein comprises a polypeptide.
  • the exogenous agent, e.g., pharmaceutical agent is a binding agent, for example, an antibody, such as, e.g., a human, humanized, or chimeric antibody, or antigen- binding fragment thereof.
  • the antibody is a monospecific, bispecific or multispecific antibody, or antigen-binding fragment thereof.
  • the antibody or antigen binding fragment thereof is a single-chain antibody or a Fab fragment.
  • the antibody or antigen-binding fragment thereof would not internalize into a target cell, e.g. , a cell other than the cell type from which the exosomes were obtained, without the aid of the placenta-derived adherent cell exosome.
  • the exogenous agent, e.g., pharmaceutical agent, loaded into the placenta-derived adherent cell exosomes described herein comprises one or more nucleic acids.
  • the one or more nucleic acids comprise a small interfering R A (siR A) or an miR A.
  • the exogenous agent, e.g., pharmaceutical agent, loaded into the placenta-derived adherent cell exosomes described herein comprises one or more gene- modifying components.
  • the one or more gene -modifying components comprise a CRISPR-Cas system.
  • the CRISPR-Cas system comprises a guide RNA.
  • the CRISPR-Cas system comprises an endonuclease.
  • the CRISPR-Cas system comprises a guide RNA and an endonuclease.
  • the CRISPR-Cas system comprises Cas9.
  • the CRISPR-Cas system comprises Cpfl .
  • the one or more gene-modifying components comprise a zinc finger nuclease.
  • the one or more gene-modifying components comprise a transcription activator-like effector nuclease (TALEN) system.
  • TALEN transcription activator-like effector nuclease
  • methods of delivering an exogenous agent, e.g., a pharmaceutical agent, to a target cell wherein the exogenous agent is loaded into a placenta-derived adherent cell exosome.
  • the target cell is a cell other than the cell type from which the exosome was obtained.
  • the exogenous agent e.g.
  • the exogenous agent e.g., pharmaceutical agent is a binding agent, for example, an antibody, such as, e.g., a human, humanized, or chimeric antibody, or antigen-binding fragment thereof.
  • an antibody such as, e.g., a human, humanized, or chimeric antibody, or antigen-binding fragment thereof.
  • the antibody is a monospecific, bispecific or multispecific antibody, or antigen- binding fragment thereof.
  • the antibody or antigen binding fragment thereof is a single-chain antibody or a Fab fragment.
  • the antibody or antigen-binding fragment thereof would not internalize into a target cell, e.g. , a cell other than the cell type from which the exosomes were obtained, without the aid of the placenta- derived adherent cell exosome.
  • the exogenous agent e.g.,
  • the pharmaceutical agent, loaded into the placenta-derived adherent cell exosomes described herein comprises one or more nucleic acids.
  • the one or more nucleic acids comprise a siRNA or an miRNA.
  • the exogenous agent, e.g., pharmaceutical agent, loaded into the placenta-derived adherent cell exosomes described herein comprises one or more gene-modifying components.
  • the one or more gene -modifying components comprise a CRISPR-Cas system.
  • the CRISPR-Cas system comprises a guide RNA.
  • the CRISPR- Cas system comprises an endonuclease.
  • the CRISPR-Cas system comprises a guide RNA and an endonuclease. In more specific embodiments, the CRISPR-Cas system comprises Cas9. In more specific embodiments, the CRISPR-Cas system comprises Cpf 1. In specific embodiments, the one or more gene-modifying components comprise a zinc finger nuclease. In specific embodiments, the one or more gene-modifying components comprise a transcription activator-like effector nuclease (TALEN) system.
  • TALEN transcription activator-like effector nuclease
  • exosomes comprising exogenous agents, for example, pharmaceutical agents
  • a subject e.g., a human
  • the exogenous agent e.g., pharmaceutical agent
  • the exogenous agent comprises a polypeptide.
  • the exogenous agent, e.g., pharmaceutical agent is a binding agent, for example, an antibody, such as, e.g., a human, humanized, or chimeric antibody, or antigen-binding fragment thereof.
  • the antibody is a monospecific, bispecific or multispecific antibody, or antigen-binding fragment thereof.
  • the antibody or antigen binding fragment thereof is a single-chain antibody or a Fab fragment. In specific embodiments, the antibody or antigen-binding fragment thereof would not internalize into a target cell without the aid of the exosome.
  • the exogenous agent, e.g., pharmaceutical agent, loaded into the placenta-derived adherent cell exosomes described herein comprises one or more nucleic acids. In specific embodiments, the one or more nucleic acids comprise a siR A or an miRNA. In certain embodiments, the exogenous agent, e.g., pharmaceutical agent, loaded into the placenta-derived adherent cell exosomes described herein comprises one or more gene-modifying components.
  • the one or more gene-modifying components comprise a CRISPR-Cas system.
  • the CRISPR-Cas system comprises a guide RNA.
  • the CRISPR-Cas system comprises an endonuclease.
  • the CRISPR-Cas system comprises a guide RNA and an endonuclease.
  • the CRISPR-Cas system comprises Cas9.
  • the CRISPR-Cas system comprises Cpfl .
  • the one or more gene -modifying components comprise a zinc finger nuclease.
  • the one or more gene -modifying components comprise a transcription activator-like effector nuclease (TALEN) system.
  • compositions comprising placenta-derived adherent cell exosomes loaded with one or more exogenous agents, for example, pharmaceutical agents.
  • the exogenous agent e.g., pharmaceutical agent
  • incorporated into the placenta-derived adherent cell exosomes described herein comprises a polypeptide.
  • the exogenous agent, e.g., pharmaceutical agent is a binding agent, for example, an antibody, such as, e.g., a human, humanized, or chimeric antibody, or antigen- binding fragment thereof.
  • the antibody is a monospecific, bispecific or multispecific antibody, or antigen-binding fragment thereof.
  • the antibody or antigen binding fragment thereof is a single-chain antibody or a Fab fragment. In specific embodiments, the antibody or antigen-binding fragment thereof would not internalize into a target cell without the aid of the exosome.
  • the exogenous agent, e.g., pharmaceutical agent, loaded into the placenta-derived adherent cell exosomes described herein comprises one or more nucleic acids. In specific embodiments, the one or more nucleic acids comprise a siRNA or an miRNA. In certain embodiments, the exogenous agent, e.g., pharmaceutical agent, loaded into the placenta-derived adherent cell exosomes described herein comprises one or more gene-modifying components.
  • the one or more gene -modifying components comprise a CRISPR-Cas system.
  • the CRISPR-Cas system comprises a guide RNA.
  • the CRISPR-Cas system comprises an endonuclease.
  • the CRISPR-Cas system comprises a guide RNA and an endonuclease. In more specific embodiments, the CRISPR-Cas system comprises Cas9. In more specific embodiments, the CRISPR-Cas system comprises Cpf 1. In specific embodiments, the one or more gene- modifying components comprise a zinc finger nuclease. In specific embodiments, the one or more gene-modifying components comprise a transcription activator-like effector nuclease (TALEN) system.
  • TALEN transcription activator-like effector nuclease
  • Figure 1 shows the results of an exosome antibody array demonstrating the existence of placenta-derived adherent cell exosomes.
  • Top panel positive control from chorionic villi mesenchymal stem cells; bottom panel placenta-derived adherent cell exosomes.
  • Figure 2A-2B Figure 2A is an electron micrograph of placenta-derived adherent cell exosomes, with arrows indicating cup-shaped structures that are a common distinguishing feature of exosomes.
  • Figure 2B shows the size distribution of placenta-derived adherent cell exosomes as determined by nanoparticle tracking assay.
  • Figures 3A-3D show the elution profiles of known molecules (Figure 3 A) as compared to exosomes from either chorionic villi mesenchymal stem cells ( Figure 3B) or the non- chorionic placenta-derived adherent cells described herein isolated under culture conditions containing or lacking serum ( Figures 3C and 3D).
  • Figures 4A-4C Figure 4A shows levels of various microRNAs contained in exosomes isolated from chorionic villi mesenchymal stem cells or from the exosomes described herein.
  • Figures 4B-4C show levels of various angiogenic proteins contained on or within the exosomes described herein.
  • Figure 5 shows the ability for placenta-derived adherent cell exosomes described herein to be taken up by certain cells of the blood.
  • Figure 6 shows the effects of placenta-derived adherent cell exosomes and placenta- derived adherent cells on the proliferation of human vascular endothelial cells.
  • Figures 7A-B show the levels of various cytokines and chemokines produced in vitro by LPS -stimulated human blood after incubation with placenta-derived adherent cells or placenta-derived adherent cell exosomes.
  • Figures 8A-8G shows the effects of placenta-derived adherent cell exosomes on vascular endothelial cell growth and proliferation.
  • Figures 8A and 8B show the ability of placenta-derived adherent cell exosomes to promote tube formation and branching of cultured vascular cells, when said exosomes are collected from placenta-derived adherent cell cultures either containing serum ( Figure 8 A) or lacking serum ( Figure 8B).
  • Figure 8C shows the relative expression of VEGF pathway genes after co-cultures with placenta-derived adherent cell exosomes.
  • Figures 8D-8G show the changes in gene expression for VEGF pathway genes over time after co-culturing vascular endothelial cells with placenta-derived adherent cells or placenta-derived adherent cell exosomes.
  • Cultured HUVECs were incubated with placenta-derived adherent cell culture supernatant (crosses), 50 ⁇ g of placenta-derived adherent cell exosomes (triangles), or culture medium (diamonds) as a control.
  • Figure 9A shows the relative levels of TNF-a and MCP-1 secreted by monocyte-derived macrophages after co-culture with placenta-derived adherent cells or placenta- derived adherent cell exosomes.
  • Figure 9B shows the level of secretion of TNF-a and IL-8 (left and middle, respectively) secreted by macrophages after co-culture with placenta-derived adherent cells or placenta-derived adherent cell exosomes. Also shown ( Figure 9B, right) is the effect of intact or lysed placenta-derived adherent cell exosomes on IL-8 secretion from monocyte-derived macrophages.
  • Placenta-Derived Adherent Cell Exosomes can be selected and identified by their morphology and/or molecular markers, as described below.
  • the placenta- derived adherent cell exosomes described herein are distinct from exosomes known in the art e.g., chorionic villi mesenchymal stem cell-derived exosomes, e.g., those described in Salomon et ah, 2013, PLOS ONE, 8:7, e68451. Accordingly, the term "placenta-derived adherent cell exosome,” as used herein, is not meant to include exosomes obtained or derived from chorionic villi mesenchymal stem cells.
  • populations of placenta-derived adherent cell exosomes described herein do not comprise cells, e.g., nucleated cells, for example placental cells, e.g., placenta-derived adherent cells.
  • the placenta-derived adherent cell exosomes described herein contain markers that can be used to identify and/or isolate said exosomes. These markers may, for example, be proteins, nucleic acids, saccharide molecules, glycosylated proteins, lipid molecules, and may exist in monomeric, oligomeric and/or multimeric form. In certain embodiments, the markers are produced by the placenta-derived adherent cell from which the exosomes are derived. In certain embodiments, the marker is provided by the placenta-derived adherent cell from which the exosomes are derived, but the marker is not expressed at a higher level by said cell.
  • the markers of placenta-derived adherent cell exosomes described herein are higher in the exosomes as compared to the cell of origin when compared to a control marker molecule.
  • the markers of placenta-derived adherent cell exosomes described herein are enriched in said exosomes as compared to exosomes obtained from another cell type ⁇ e.g., the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451 and pre-adipocyte mesenchymal stem cells), wherein the exosomes are obtained through identical methods and wherein the cells from which the exosomes are derived are maintained under identical conditions.
  • exosomes allow for the retention of markers on the surface of the exosome and/or contained within the exosome.
  • marker molecules may exist partially within the exosome, partially on the outer surface of the exosome and/or across the phospholipid bilayer of the exosome.
  • the markers associated with the placenta-derived adherent cell exosomes described herein are proteins.
  • the markers are transmembrane proteins that are anchored within the exosome phospholipid bilayer, or are anchored across the exosome phospholipid bilayer such that portions of the protein molecule are within the exosome while portions of the same molecule are exposed to the outer surface of the exosome.
  • the markers are contained entirely within the exosome.
  • the markers associated with the placenta-derived adherent cell exosomes described herein are nucleic acids.
  • said nucleic acids are non-coding R A molecules, e.g., micro-R As (miR As).
  • the placenta-derived adherent cell exosomes described herein comprise surface markers that allow for their identification and that can be used to isolate/obtain substantially pure populations of placenta-derived adherent cell exosomes free from their placenta-derived adherent cells of origin and other cellular and non-cellular material.
  • Methods of for determining exosome surface marker composition are known in the art. For example, exosomal surface markers can be detected by fluorescence-activated cell sorting (FACS) or Western blotting.
  • placenta-derived adherent cell exosomes described herein contain distinct surface markers that allow them to be distinguished from other exosomes known in the art.
  • the placenta-derived adherent cell exosomes provided herein comprise one, two, three, four, five, or more of the following markers: CD9, CD10, CD13, CD29, CD44, CD49b, CD49c, CD55, CD59, CD63, CD73, CD81, CD82, CD90, CD98, CD105, CD141, CD142, CD151 , CD164, CD295, CD200 (as determinable by, e.g., FACS).
  • the placenta-derived adherent cell exosomes described herein are CD55 + and CD10 + as determined, e.g., by flow cytometry, for example, by FACS.
  • the placenta-derived adherent cell exosomes described herein are CD10 + and CD55 + (as determined by, e.g., FACS) and additionally contain CD82, CD142, CD49c, and CD90 at a level higher than chorionic villi mesenchymal stem cell exosomes or pre- adipocyte mesenchymal stem cell exosomes ⁇ e.g., the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451).
  • the placenta-derived adherent cell exosomes described herein are CD9 + .
  • the placenta-derived adherent cell exosomes described herein are CD10 + .
  • the placenta-derived adherent cell exosomes described herein are CD13 + .
  • the placenta-derived adherent cell exosomes described herein are CD29 .
  • the placenta-derived adherent cell exosomes described herein are CD44 + .
  • the placenta-derived adherent cell exosomes described herein are CD49b + .
  • the placenta-derived adherent cell exosomes described herein are CD49c + . In another specific embodiment, the placenta-derived adherent cell exosomes described herein are CD55 + . In another specific embodiment, the placenta-derived adherent cell exosomes described herein are CD59 + . In another specific embodiment, the placenta-derived adherent cell exosomes described herein are CD63 + . In another specific embodiment, the placenta-derived adherent cell exosomes described herein are CD73 + . In another specific embodiment, the placenta-derived adherent cell exosomes described herein are CD81 + .
  • the placenta-derived adherent cell exosomes described herein are CD82 + . In another specific embodiment, the placenta-derived adherent cell exosomes described herein are CD90 + . In another specific embodiment, the placenta-derived adherent cell exosomes described herein are CD98 + . In another specific embodiment, the placenta-derived adherent cell exosomes described herein are CD105 + . In another specific embodiment, the placenta-derived adherent cell exosomes described herein are CD141 + . In another specific embodiment, the placenta- derived adherent cell exosomes described herein are CD142 + .
  • the placenta-derived adherent cell exosomes described herein are CD 151 + . In another specific embodiment, the placenta-derived adherent cell exosomes described herein are CD164 + . In another specific embodiment, the placenta-derived adherent cell exosomes described herein are CD295 + . In another specific embodiment, the placenta-derived adherent cell exosomes described herein are CD200 + . Determination of the presence of such markers can be made, e.g. , by flow cytometry, for example, by FACS. In another embodiment, described herein are populations of placenta-derived adherent cell exosomes containing any combination of the above-referenced surface markers.
  • the placenta-derived adherent cell exosomes described herein are CD9 + and additionally comprise one or more of the markers selected from the group of CDIO, CD13, CD29, CD44, CD49b, CD49c, CD55, CD59, CD63, CD73, CD81, CD82, CD90, CD98, CD105, CD141, CD142, CD151, CD164, CD295, and CD200.
  • the placenta-derived adherent cell exosomes described herein are CD10 + and additionally comprise one or more of the markers selected from the group of CD9, CD13, CD29, CD44, CD49b, CD49c, CD55, CD59, CD63, CD73, CD81, CD82, CD90, CD98, CD105, CD141, CD142, CD151, CD164, CD295, and CD200.
  • the placenta-derived adherent cell exosomes described herein are CD13 + and additionally comprise one or more of the markers selected from the group of CD9, CD10, CD29, CD44, CD49b, CD49c, CD55, CD59, CD63, CD73, CD81, CD82, CD90, CD98, CD105, CD141, CD142, CD151, CD164, CD295, and CD200.
  • the placenta-derived adherent cell exosomes described herein are CD29 + and additionally comprise one or more of the markers selected from the group of CD9, CD10, CD13, CD44, CD49b, CD49c, CD55, CD59, CD63, CD73, CD81, CD82, CD90, CD98, CD105, CD141, CD142, CD151, CD164, CD295, and CD200.
  • the placenta-derived adherent cell exosomes described herein are CD44 + and additionally comprise one or more of the markers selected from the group of CD9, CD10, CD13, CD29, CD49b, CD49c, CD55, CD59, CD63, CD73, CD81, CD82, CD90, CD98, CD105, CD141, CD142, CD151, CD164, CD295, and CD200.
  • the placenta-derived adherent cell exosomes described herein are CD49b + and additionally comprise one or more of the markers selected from the group of CD9, CD10, CD13, CD29, CD44, CD49c, CD55, CD59, CD63, CD73, CD81, CD82, CD90, CD98, CD105, CD141, CD142, CD151, CD164, CD295, and CD200.
  • the placenta-derived adherent cell exosomes described herein are CD49c + and additionally comprise one or more of the markers selected from the group of CD9, CD10, CD13, CD29, CD44, CD49b, CD55, CD59, CD63, CD73, CD81, CD82, CD90, CD98, CD105, CD141, CD142, CD151, CD164, CD295, and CD200.
  • the placenta-derived adherent cell exosomes described herein are CD55 + and additionally comprise one or more of the markers selected from the group of CD9, CD10, CD13, CD29, CD44, CD49b, CD49c, CD59, CD63, CD73, CD81, CD82, CD90, CD98, CD105, CD141, CD142, CD151, CD164, CD295, and CD200.
  • the placenta-derived adherent cell exosomes described herein are CD59 + and additionally comprise one or more of the markers selected from the group of CD9, CD10, CD13, CD29, CD44, CD49b, CD49c, CD55, CD63, CD73, CD81, CD82, CD90, CD98, CD105, CD141, CD142, CD151, CD164, CD295, and CD200.
  • the placenta-derived adherent cell exosomes described herein are CD63 + and additionally comprise one or more of the markers selected from the group of CD9, CDIO, CD13, CD29, CD44, CD49b, CD49c, CD55, CD59, CD73, CD81, CD82, CD90, CD98, CD105, CD141, CD142, CD151, CD164, CD295, and CD200.
  • the placenta-derived adherent cell exosomes described herein are CD73 + and additionally comprise one or more of the markers selected from the group of CD9, CDIO, CD13, CD29, CD44, CD49b, CD49c, CD55, CD59, CD63, CD81, CD82, CD90, CD98, CD105, CD141, CD142, CD151, CD164, CD295, and CD200.
  • the placenta-derived adherent cell exosomes described herein are CD81 + and additionally comprise one or more of the markers selected from the group of CD9, CDIO, CD13, CD29, CD44, CD49b, CD49c, CD55, CD59, CD63, CD73, CD82, CD90, CD98, CD105, CD141, CD142, CD151, CD164, CD295, and CD200.
  • the placenta-derived adherent cell exosomes described herein are CD82 + and additionally comprise one or more of the markers selected from the group of CD9, CDIO, CD13, CD29, CD44, CD49b, CD49c, CD55, CD59, CD63, CD73, CD81, CD90, CD98, CD105, CD141, CD142, CD151, CD164, CD295, and CD200.
  • the placenta-derived adherent cell exosomes described herein are CD90 + and additionally comprise one or more of the markers selected from the group of CD9, CDIO, CD13, CD29, CD44, CD49b, CD49c, CD55, CD59, CD63, CD73, CD81, CD82, CD98, CD105, CD141, CD142, CD151, CD164, CD295, and CD200.
  • the placenta-derived adherent cell exosomes described herein are CD98 + and additionally comprise one or more of the markers selected from the group of CD9, CDIO, CD13, CD29, CD44, CD49b, CD49c, CD55, CD59, CD63, CD73, CD81, CD82, CD90, CD105, CD141, CD142, CD151, CD164, CD295, and CD200.
  • the placenta-derived adherent cell exosomes described herein are CD105 + and additionally comprise one or more of the markers selected from the group of CD9, CDIO, CD13, CD29, CD44, CD49b, CD49c, CD55, CD59, CD63, CD73, CD81, CD82, CD90, CD98 , CD141, CD142, CD151, CD164, CD295, and CD200.
  • the placenta-derived adherent cell exosomes described herein are CD141 + and additionally comprise one or more of the markers selected from the group of CD9, CD10, CD13, CD29, CD44, CD49b, CD49c, CD55, CD59, CD63, CD73, CD81, CD82, CD90, CD98, CD105, CD142, CD151, CD164, CD295, and CD200.
  • the placenta-derived adherent cell exosomes described herein are CD142 + and additionally comprise one or more of the markers selected from the group of CD9, CD10, CD13, CD29, CD44, CD49b, CD49c, CD55, CD59, CD63, CD73, CD81, CD82, CD90, CD98, CD105, CD141, CD151, CD164, CD295, and CD200.
  • the placenta-derived adherent cell exosomes described herein are CD151 + and additionally comprise one or more of the markers selected from the group of CD9, CD10, CD13, CD29, CD44, CD49b, CD49c, CD55, CD59, CD63, CD73, CD81, CD82, CD90, CD98, CD105, CD141, CD142, CD164, CD295, and CD200.
  • the placenta-derived adherent cell exosomes described herein are CD164 + and additionally comprise one or more of the markers selected from the group of CD9, CD10, CD13, CD29, CD44, CD49b, CD49c, CD55, CD59, CD63, CD73, CD81, CD82, CD90, CD98, CD105, CD141, CD142, CD151, CD295, and CD200.
  • the placenta-derived adherent cell exosomes described herein are CD295 + and additionally comprise one or more of the markers selected from the group of CD9, CD10, CD13, CD29, CD44, CD49b, CD49c, CD55, CD59, CD63, CD73, CD81, CD82, CD90, CD98, CD105, CD141, CD142, CD151, and CD200.
  • the placenta-derived adherent cell exosomes described herein are CD200 + and additionally comprise one or more of the markers selected from the group of CD9, CD10, CD13, CD29, CD44, CD49b, CD49c, CD55, CD59, CD63, CD73, CD81, CD82, CD90, CD98, CD105, CD141, CD142, CD164, and CD295.
  • the placenta-derived adherent cell exosomes described herein are CD49b + , CD49c + , CD98 + , CD29 + , CD142 + , CD10 + , CD47 + , CD55 + , CD90 + , CD147 + , CD151 + , CD166 + , CD82 + and CD200 + .
  • the placenta-derived adherent cell exosomes described herein generally do not comprise the surface markers CD3, CD1 lb, CD14, CD19, CD33, CD192, HLA-A, HLA-B, HLA-C, HLA-DR, CD1 lc or CD34.
  • the placenta-derived adherent cell exosomes described herein are CD3 " .
  • the placenta-derived adherent cell exosomes described herein are CD1 lb " .
  • the placenta-derived adherent cell exosomes described herein are CD 14 " .
  • the placenta- derived adherent cell exosomes described herein are CD 19 " . In another embodiment, the placenta-derived adherent cell exosomes described herein are CD33 " . In another embodiment, the placenta-derived adherent cell exosomes described herein are CD 192 " . In another embodiment, the placenta-derived adherent cell exosomes described herein are HLA-A " . In another embodiment, the placenta-derived adherent cell exosomes described herein are HLA-B " . In another embodiment, the placenta-derived adherent cell exosomes described herein are HLA- C " .
  • the placenta-derived adherent cell exosomes described herein are HLA-DR " . In another embodiment, the placenta-derived adherent cell exosomes described herein are CD1 lc " . In another embodiment, the placenta-derived adherent cell exosomes described herein are CD34 " .
  • the placenta-derived adherent cell exosomes described herein are CD3 " and do not comprise one or more of the markers selected from the group of CD1 lb, CD14, CD19, CD33, CD192, HLA-A, HLA-B, HLA-C, HLA-DR, CDl lc and CD34.
  • the placenta-derived adherent cell exosomes described herein are CD1 lb " and do not comprise one or more of the markers selected from the group of CD3, CD14, CD19, CD33, CD192, HLA-A, HLA-B, HLA-C, HLA-DR, CDl lc and CD34.
  • the placenta-derived adherent cell exosomes described herein are CD 14 " and do not comprise one or more of the markers selected from the group of CD3, CDl lb, CD19, CD33, CD192, HLA-A, HLA-B, HLA-C, HLA-DR, CDl lc and CD34.
  • the placenta-derived adherent cell exosomes described herein are CD 19 " and do not comprise one or more of the markers selected from the group of CD3, CDl lb, CD14, CD33, CD192, HLA-A, HLA-B, HLA-C, HLA-DR, CDl lc and CD34.
  • the placenta-derived adherent cell exosomes described herein are CD33 " and do not comprise one or more of the markers selected from the group of CD3, CDl lb, CD14, CD19, CD192, HLA-A, HLA-B, HLA-C, HLA-DR, CDl lc and CD34.
  • the placenta-derived adherent cell exosomes described herein are CD 192 " and do not comprise one or more of the markers selected from the group of CD3, CDl lb, CD14, CD19, CD33, HLA-A, HLA-B, HLA-C, HLA-DR, CDl lc and CD34.
  • the placenta-derived adherent cell exosomes described herein are HLA-A " and do not comprise one or more of the markers selected from the group of CD3, CDl lb, CD14, CD19, CD33, CD192, HLA-B, HLA-C, HLA-DR, CDl lc and CD34.
  • the placenta-derived adherent cell exosomes described herein are HLA-B " and do not comprise one or more of the markers selected from the group of CD3, CDl lb, CD14, CD19, CD33, CD192, HLA-A, HLA-C, HLA-DR, CDl lc and CD34.
  • the placenta-derived adherent cell exosomes described herein are HLA-C " and do not comprise one or more of the markers selected from the group of CD3, CDl lb, CD14, CD19, CD33, CD192, HLA-A, HLA-B, HLA-DR, CDl lc and CD34.
  • the placenta-derived adherent cell exosomes described herein are HLA-DR " and do not comprise one or more of the markers selected from the group of CD3, CDl lb, CD14, CD19, CD33, CD192, HLA-A, HLA-B, HLA-C, CDl lc and CD34.
  • the placenta-derived adherent cell exosomes described herein are CD1 lc " and do not comprise one or more of the markers selected from the group of CD3, CDl lb, CD14, CD19, CD33, CD192, HLA-A, HLA-B, HLA-C, HLA-DR and CD34.
  • the placenta-derived adherent cell exosomes described herein are CD34 " and do not comprise one or more of the markers selected from the group of CD3, CDl lb, CD14, CD19, CD33, CD192, HLA-A, HLA-B, HLA-C, HLA-DR and CDl lc.
  • the placenta-derived adherent cell exosomes described herein are CD3 " , CDl lb “ , CD14 “ , CD19 “ , CD33 “ , CD192 “ , HLA-A “ , HLA-B “ , HLA-C “ , HLA-DR “ , CDl lc “ and CD34 “ .
  • the placenta-derived adherent cell exosomes described herein are CD9+ and additionally comprise one or more of the markers selected from the group of CD10, CD13, CD29, CD44, CD49b, CD49c, CD55, CD59, CD63, CD73, CD81, CD82, CD90, CD98, CD105, CD141, CD142, CD151, CD164, CD295, and CD200, while further lacking one or more of the markers selected from the group of CD3, CD1 lb, CD14, CD19, CD33, CD192, HLA-A, HLA-B, HLA-C, HLA-DR, CDl lc and CD34.
  • the placenta-derived adherent cell exosomes described herein are CD 10+ and additionally comprise one or more of the markers selected from the group of CD9, CD13, CD29, CD44, CD49b, CD49c, CD55, CD59, CD63, CD73, CD81, CD82, CD90, CD98, CD105, CD141, CD142, CD151, CD164, CD295, and CD200, while further lacking one or more of the markers selected from the group of CD3, CD1 lb, CD14, CD19, CD33, CD192, HLA-A, HLA-B, HLA-C, HLA-DR, CD1 lc and CD34.
  • the placenta-derived adherent cell exosomes described herein are CD 13+ and additionally comprise one or more of the markers selected from the group of CD9, CDIO, CD29, CD44, CD49b, CD49c, CD55, CD59, CD63, CD73, CD81, CD82, CD90, CD98, CD105, CD141, CD142, CD151, CD164, CD295, and CD200, while further lacking one or more of the markers selected from the group of CD3, CD1 lb, CD14, CD19, CD33, CD192, HLA-A, HLA-B, HLA-C, HLA-DR, CD1 lc and CD34.
  • the placenta-derived adherent cell exosomes described herein are CD29+ and additionally comprise one or more of the markers selected from the group of CD9, CDIO, CD13, CD44, CD49b, CD49c, CD55, CD59, CD63, CD73, CD81, CD82, CD90, CD98, CD105, CD141, CD142, CD151, CD164, CD295, and CD200, while further lacking one or more of the markers selected from the group of CD3, CD1 lb, CD14, CD19, CD33, CD192, HLA-A, HLA-B, HLA-C, HLA-DR, CD1 lc and CD34.
  • the placenta-derived adherent cell exosomes described herein are CD44+ and additionally comprise one or more of the markers selected from the group of CD9, CDIO, CD13, CD29, CD49b, CD49c, CD55, CD59, CD63, CD73, CD81, CD82, CD90, CD98, CD105, CD141, CD142, CD151, CD164, CD295, and CD200, while further lacking one or more of the markers selected from the group of CD3, CD1 lb, CD14, CD19, CD33, CD192, HLA-A, HLA-B, HLA-C, HLA-DR, CD1 lc and CD34.
  • the placenta-derived adherent cell exosomes described herein are CD49b+ and additionally comprise one or more of the markers selected from the group of CD9, CDIO, CD13, CD29, CD44, CD49c, CD55, CD59, CD63, CD73, CD81, CD82, CD90, CD98, CD105, CD141, CD142, CD151, CD164, CD295, and CD200, while further lacking one or more of the markers selected from the group of CD3, CD1 lb, CD14, CD19, CD33, CD192, HLA-A, HLA-B, HLA-C, HLA-DR, CDl lc and CD34.
  • the placenta-derived adherent cell exosomes described herein are CD49c+ and additionally comprise one or more of the markers selected from the group of CD9, CDIO, CD13, CD29, CD44, CD49b, CD55, CD59, CD63, CD73, CD81, CD82, CD90, CD98, CD105, CD141, CD142, CD151, CD164, CD295, and CD200, while further lacking one or more of the markers selected from the group of CD3, CD1 lb, CD14, CD19, CD33, CD192, HLA-A, HLA-B, HLA-C, HLA-DR, CDl lc and CD34.
  • the placenta-derived adherent cell exosomes described herein are CD55+ and additionally comprise one or more of the markers selected from the group of CD9, CDIO, CD13, CD29, CD44, CD49b, CD49c, CD59, CD63, CD73, CD81, CD82, CD90, CD98, CD105, CD141, CD142, CD151, CD164, CD295, and CD200., while further lacking one or more of the markers selected from the group of CD3, CD1 lb, CD14, CD19, CD33, CD192, HLA-A, HLA-B, HLA-C, HLA-DR, CD1 lc and CD34.
  • the placenta-derived adherent cell exosomes described herein are CD59+ and additionally comprise one or more of the markers selected from the group of CD9, CDIO, CD13, CD29, CD44, CD49b, CD49c, CD55, CD63, CD73, CD81, CD82, CD90, CD98, CD105, CD141, CD142, CD151, CD164, CD295, and CD200, while further lacking one or more of the markers selected from the group of CD3, CD1 lb, CD14, CD19, CD33, CD192, HLA-A, HLA-B, HLA-C, HLA-DR, CD1 lc and CD34.
  • the placenta-derived adherent cell exosomes described herein are CD63+ and additionally comprise one or more of the markers selected from the group of CD9, CDIO, CD13, CD29, CD44, CD49b, CD49c, CD55, CD59, CD73, CD81, CD82, CD90, CD98, CD105, CD141, CD142, CD151, CD164, CD295, and CD200, while further lacking one or more of the markers selected from the group of CD3, CD1 lb, CD14, CD19, CD33, CD192, HLA-A, HLA-B, HLA-C, HLA-DR, CD1 lc and CD34.
  • the placenta-derived adherent cell exosomes described herein are CD73+ and additionally comprise one or more of the markers selected from the group of CD9, CDIO, CD13, CD29, CD44, CD49b, CD49c, CD55, CD59, CD63, CD81, CD82, CD90, CD98, CD105, CD141, CD142, CD151, CD164, CD295, and CD200, while further lacking one or more of the markers selected from the group of CD3, CD1 lb, CD14, CD19, CD33, CD192, HLA-A, HLA-B, HLA-C, HLA-DR, CD1 lc and CD34.
  • the placenta-derived adherent cell exosomes described herein are CD81+ and additionally comprise one or more of the markers selected from the group of CD9, CDIO, CD13, CD29, CD44, CD49b, CD49c, CD55, CD59, CD63, CD73, CD82, CD90, CD98, CD105, CD141, CD142, CD151, CD164, CD295, and CD200, while further lacking one or more of the markers selected from the group of CD3, CD1 lb, CD14, CD19, CD33, CD192, HLA-A, HLA-B, HLA-C, HLA-DR, CD1 lc and CD34.
  • the placenta-derived adherent cell exosomes described herein are CD82+ and additionally comprise one or more of the markers selected from the group of CD9, CD10, CD13, CD29, CD44, CD49b, CD49c, CD55, CD59, CD63, CD73, CD81, CD90, CD98, CD105, CD141, CD142, CD151, CD164, CD295, and CD200, while further lacking one or more of the markers selected from the group of CD3, CD1 lb, CD14, CD19, CD33, CD192, HLA-A, HLA-B, HLA-C, HLA-DR, CD1 lc and CD34.
  • the placenta-derived adherent cell exosomes described herein are CD90+ and additionally comprise one or more of the markers selected from the group of CD9, CD10, CD13, CD29, CD44, CD49b, CD49c, CD55, CD59, CD63, CD73, CD81, CD82, CD98, CD105, CD141, CD142, CD151, CD164, CD295, and CD200, while further lacking one or more of the markers selected from the group of CD3, CD1 lb, CD14, CD19, CD33, CD192, HLA-A, HLA-B, HLA-C, HLA-DR, CD1 lc and CD34.
  • the placenta-derived adherent cell exosomes described herein are CD98+ and additionally comprise one or more of the markers selected from the group of CD9, CD10, CD13, CD29, CD44, CD49b, CD49c, CD55, CD59, CD63, CD73, CD81, CD82, CD90, CD 105, CD 141, CD 142, CD 151, CD 164, CD295, and CD200, while further lacking one or more of the markers selected from the group of CD3, CD1 lb, CD14, CD19, CD33, CD192, HLA-A, HLA-B, HLA-C, HLA-DR, CD1 lc and CD34.
  • the placenta-derived adherent cell exosomes described herein are CD 105+ and additionally comprise one or more of the markers selected from the group of CD9, CD10, CD13, CD29, CD44, CD49b, CD49c, CD55, CD59, CD63, CD73, CD81, CD82, CD90, CD98, CD141, CD142, CD151, CD164, CD295, and CD200, while further lacking one or more of the markers selected from the group of CD3, CD1 lb, CD14, CD19, CD33, CD192, HLA-A, HLA-B, HLA-C, HLA-DR, CD1 lc and CD34.
  • the placenta-derived adherent cell exosomes described herein are CD 141+ and additionally comprise one or more of the markers selected from the group of CD9, CD10, CD13, CD29, CD44, CD49b, CD49c, CD55, CD59, CD63, CD73, CD81, CD82, CD90, CD98, CD105, CD142, CD151, CD164, CD295, and CD200, while further lacking one or more of the markers selected from the group of CD3, CD1 lb, CD14, CD19, CD33, CD192, HLA-A, HLA-B, HLA-C, HLA-DR, CD1 lc and CD34.
  • the placenta-derived adherent cell exosomes described herein are CD 142+ and additionally comprise one or more of the markers selected from the group of CD9, CD10, CD13, CD29, CD44, CD49b, CD49c, CD55, CD59, CD63, CD73, CD81, CD82, CD90, CD98, CD105, CD141, CD151, CD164, CD295, and CD200, while further lacking one or more of the markers selected from the group of CD3, CD1 lb, CD14, CD19, CD33, CD192, HLA-A, HLA-B, HLA-C, HLA-DR, CD1 lc and CD34.
  • the placenta-derived adherent cell exosomes described herein are CD 151+ and additionally comprise one or more of the markers selected from the group of CD9, CD10, CD13, CD29, CD44, CD49b, CD49c, CD55, CD59, CD63, CD73, CD81, CD82, CD90, CD98, CD105, CD141, CD142, CD164, CD295, and CD200, while further lacking one or more of the markers selected from the group of CD3, CD1 lb, CD14, CD19, CD33, CD192, HLA-A, HLA-B, HLA-C, HLA-DR, CD1 lc and CD34.
  • the placenta-derived adherent cell exosomes described herein are CD 164+ and additionally comprise one or more of the markers selected from the group of CD9, CD10, CD13, CD29, CD44, CD49b, CD49c, CD55, CD59, CD63, CD73, CD81, CD82, CD90, CD98, CD105, CD141, CD142, CD151, CD295, and CD200, while further lacking one or more of the markers selected from the group of CD3, CD1 lb, CD14, CD19, CD33, CD192, HLA-A, HLA-B, HLA-C, HLA-DR, CD1 lc and CD34.
  • the placenta-derived adherent cell exosomes described herein are CD295+ and additionally comprise one or more of the markers selected from the group of CD9, CD10, CD13, CD29, CD44, CD49b, CD49c, CD55, CD59, CD63, CD73, CD81, CD82, CD90, CD98, CD105, CD141, CD142, CD151, and CD200, while further lacking one or more of the markers selected from the group of CD3, CD1 lb, CD14, CD19, CD33, CD192, HLA-A, HLA-B, HLA-C, HLA-DR, CDl lc and CD34.
  • the placenta-derived adherent cell exosomes described herein are CD200+ and additionally comprise one or more of the markers selected from the group of CD9, CD10, CD13, CD29, CD44, CD49b, CD49c, CD55, CD59, CD63, CD73, CD81, CD82, CD90, CD98, CD105, CD141, CD142, CD164, and CD295, while further lacking one or more of the markers selected from the group of CD3, CDl lb, CD14, CD19, CD33, CD192, HLA-A, HLA-B, HLA-C, HLA-DR, CDl lc and CD34.
  • the placenta-derived adherent cell exosomes described herein are CD9 + , CD10 + , CD13 + , CD29 + , CD44 + , CD49b + , CD49c + , CD55 + , CD59 + , CD63 + , CD73 + , CD81 + , CD82 + , CD90 + , CD98 + , CD105 + , CD141 + , CD142 + , CD151 + , CD164 + , CD295 , and CD200 while further lacking one or more of the markers selected from the group of CD3, CDl lb, CD14, CD19, CD33, CD192, HLA-A, HLA-B, HLA-C, HLA-DR, CDl lc and CD34.
  • the placenta-derived adherent cell exosomes described herein are CD3 , CDl lb “ , CD14 “ , CD19 “ , CD33 “ , CD192 “ , HLA-A “ , HLA-B “ , HLA-C “ , HLA-DR “ , CDl lc “ and CD34 " while additionally comprising one or more of the markers selected from the group of CD9, CD10, CD13, CD29, CD44, CD49b, CD49c, CD55, CD59, CD63, CD73, CD81, CD82, CD90, CD98, CD105, CD141, CD142, CD151, CD164, CD295, and CD200.
  • the placenta-derived adherent cell exosomes described herein are CD9 + , CD10 + , CD13 + , CD29 + , CD44 + , CD49b + , CD49c + , CD55 + , CD59 + , CD63 + , CD73 + , CD81 + , CD82 + , CD90 + , CD98 + , CD105 + , CD141 + , CD142 + , CD151 + , CD164 + , CD295 + , CD200 + , CD3 " , CDl lb “ , CD14 “ , CD19 “ , CD33 “ , CD192 “ , HLA-A “ , HLA-B “ , HLA-C “ , HLA-DR “ , CDl lc “ and CD34 " .
  • the placenta-derived adherent cell exosomes described herein do not contain detectable levels of CD4, CD5, CD6, CD7, CD8, CD16, CD24, CD25, CD26, CD27, CD32, CD35, CD37, CD39, CD45, CD46, CD54, CD56, CD61, CD74, CD86,CD88, CD91, CD99, CD103, CD108, CDl 12, CDl 17, CDl 19, CD120a, CD123, CD126, CD130, CD134, CD138, CD140a, CD140b, CD144, CD146, CD147, CD152, CD163, CD183, CD184, CD 186, CD191, CD 194, CD 196, CDwl98, CD202b, CD220, CD221, CD235a, CD252, CD266, CD271, CD273, CD274, CD318, CD326, CD333, CD334, HLA-DP, HLA-DQ, HLA-G, IgD, IgM, NG2, PDGF
  • the placenta-derived adherent cell exosomes described herein are CD82 + and contain a low level of CD 141 (i.e., are CD 141 (low)) as determined, e.g., by flow cytometry, for example, by FACS.
  • the placenta-derived adherent cell exosomes described herein comprise a surface marker at a greater amount than exosomes known in the art, as determinable by, e.g., FACS.
  • the placenta-derived adherent cell exosomes described herein comprise a higher amount of CD49c, CD82, CD90, and/or CD 142 than the amount of said marker(s) in a non placenta-derived adherent cell exosome.
  • the placenta-derived adherent cell exosomes described herein comprise a higher amount of CD49c, CD82, CD90, and/or CD 142 than the amount of said marker(s) that is present in exosomes derived from either pre-adipocyte mesenchymal stem cells or chorionic villi mesenchymal stem cells (e.g., the chorionic villi mesenchymal stem cells described in Salomon et ah, 2013, PLOS ONE, 8:7, e68451).
  • the placenta-derived adherent cell exosomes described herein comprise a higher amount of CD49c, CD73, CD82, CD90, and/or CD 142 than the amount of said marker(s) that is present in exosomes derived from pre- adipocyte mesenchymal stem cells.
  • the placenta-derived adherent cell exosomes described herein comprise a lower amount of CD 164 than the amount of said marker(s) in a non placenta- derived adherent cell exosome.
  • the placenta-derived adherent cell exosomes described herein comprise a lower amount of CD 164 than the amount of said marker(s) that is present in exosomes derived from pre-adipocyte mesenchymal stem cells or chorionic villi mesenchymal stem cells (e.g.
  • the placenta-derived adherent cell exosomes described herein comprise CD 164 at a level two-fold, three-fold, four-fold, five-fold, six-fold, seven- fold, eight- fold, nine-fold, or ten- fold lower than exosomes derived from chorionic villi mesenchymal stem cells (e.g.
  • flow cytometry for example, by FACS
  • the placenta-derived adherent cell exosomes described herein comprise CD 164 at a level two-fold to three-fold, three-fold to four- fold, fourfold to five-fold, five-fold to six-fold, six-fold to seven- fold, seven- fold to eight- fold, eight- fold to nine-fold or nine-fold to ten-fold lower than exosomes derived from chorionic villi mesenchymal stem cells (e.g., the chorionic villi mesenchymal stem cells described in Salomon et al., 2013, PLOS ONE, 8:7, e68451) or pre-adipocyte mesenchymal stem cells, wherein CD164 content is measured under the same experimental conditions (e.g., by flow cytometry, for example, by FACS), wherein the exosomes are harvested under like conditions, and wherein the cells of origin are grown under like conditions.
  • chorionic villi mesenchymal stem cells e.g., the
  • the placenta-derived adherent cell exosomes described herein comprise CD 164 at a level two-fold, three-fold, fourfold, five-fold, six-fold, seven- fold, eight- fold, nine-fold, or ten-fold lower than exosomes derived from chorionic villi mesenchymal stem cells (e.g., the chorionic villi mesenchymal stem cells described in Salomon et al., 2013, PLOS ONE, 8:7, e68451) or pre-adipocyte mesenchymal stem cells, wherein CD 164 content is measured under the same experimental conditions (e.g., by flow cytometry, for example, by FACS), and wherein the same number and/or mass of exosomes is used for each sample.
  • chorionic villi mesenchymal stem cells e.g., the chorionic villi mesenchymal stem cells described in Salomon et al., 2013, PLOS ONE, 8
  • the placenta-derived adherent cell exosomes described herein comprise CD 164 at a level two-fold to three-fold, three-fold to fourfold, four- fold to five-fold, five-fold to six-fold, six-fold to seven-fold, seven-fold to eight- fold, eight- fold to nine-fold or nine-fold to ten- fold lower than exosomes derived from chorionic villi mesenchymal stem cells (e.g., the chorionic villi mesenchymal stem cells described in Salomon et al., 2013, PLOS ONE, 8:7, e68451) or pre-adipocyte mesenchymal stem cells, wherein CD164 content is measured under the same experimental conditions (e.g., by flow cytometry, for example, by FACS), and wherein the same number and/or mass of exosomes is used for each sample.
  • chorionic villi mesenchymal stem cells e.g., the chorionic vill
  • the placenta-derived adherent cell exosomes described herein comprise CD49c at a level two-fold, three-fold, four-fold, five-fold, six-fold, seven- fold, eight- fold, nine-fold, or ten- fold higher than exosomes derived from chorionic villi mesenchymal stem cells (e.g., the chorionic villi mesenchymal stem cells described in Salomon et al., 2013, PLOS ONE, 8:7, e68451) or pre-adipocyte mesenchymal stem cells, wherein CD49c content is measured under the same experimental conditions (e.g., by flow cytometry, for example, by FACS), wherein the exosomes are harvested under like conditions, and wherein the cells of origin are grown under like conditions.
  • chorionic villi mesenchymal stem cells e.g., the chorionic villi mesenchymal stem cells described in Salomon et al., 2013,
  • the placenta- derived adherent cell exosomes described herein comprise CD49c at a level two-fold to threefold, three-fold to four- fold, four- fold to five-fold, five-fold to six-fold, six-fold to seven- fold, seven- fold to eight- fold, eight- fold to nine-fold or nine-fold to ten-fold higher than exosomes derived from chorionic villi mesenchymal stem cells (e.g., the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451) or pre-adipocyte mesenchymal stem cells, wherein CD49c content is measured under the same experimental conditions (e.g., by flow cytometry, for example, by FACS), wherein the exosomes are harvested under like conditions, and wherein the cells of origin are grown under like conditions.
  • chorionic villi mesenchymal stem cells e.g., the
  • the placenta-derived adherent cell exosomes described herein comprise CD49c at a level two-fold, three-fold, four-fold, five-fold, six-fold, seven-fold, eight-fold, nine-fold, or tenfold higher than exosomes derived from chorionic villi mesenchymal stem cells (e.g., the chorionic villi mesenchymal stem cells described in Salomon et al., 2013, PLOS ONE, 8:7, e68451) or pre-adipocyte mesenchymal stem cells, wherein CD49c content is measured under the same experimental conditions (e.g., by flow cytometry, for example, by FACS), and wherein the same number and/or mass of exosomes is used for each sample.
  • chorionic villi mesenchymal stem cells e.g., the chorionic villi mesenchymal stem cells described in Salomon et al., 2013, PLOS ONE, 8
  • the placenta-derived adherent cell exosomes described herein comprise CD49c at a level two-fold to three-fold, three-fold to four- fold, four-fold to five-fold, five-fold to six-fold, six-fold to seven- fold, seven-fold to eight- fold, eight- fold to nine-fold or nine-fold to ten-fold higher than exosomes derived from chorionic villi mesenchymal stem cells (e.g., the chorionic villi mesenchymal stem cells described in Salomon et al., 2013, PLOS ONE, 8:7, e68451) or pre- adipocyte mesenchymal stem cells, wherein CD49c content is measured under the same experimental conditions (e.g., by flow cytometry, for example, by FACS), and wherein the same number and/or mass of exosomes is used for each sample.
  • chorionic villi mesenchymal stem cells e.g., the chori
  • the placenta-derived adherent cell exosomes described herein comprise CD73 at a level two-fold, three-fold, four-fold, five-fold, six-fold, seven- fold, eight- fold, nine-fold, or ten- fold higher than exosomes derived from chorionic villi mesenchymal stem cells (e.g., the chorionic villi mesenchymal stem cells described in Salomon et al., 2013, PLOS ONE, 8:7, e68451) or pre-adipocyte mesenchymal stem cells, wherein CD73 content is measured under the same experimental conditions (e.g., by flow cytometry, for example, by FACS), wherein the exosomes are harvested under like conditions, and wherein the cells of origin are grown under like conditions.
  • chorionic villi mesenchymal stem cells e.g., the chorionic villi mesenchymal stem cells described in Salomon et al., 2013, PLOS
  • the placenta- derived adherent cell exosomes described herein comprise CD73 at a level two-fold to three-fold, three-fold to four- fold, four-fold to five-fold, five-fold to six-fold, six-fold to seven- fold, sevenfold to eight- fold, eight-fold to nine-fold or nine-fold to ten- fold higher than exosomes derived from chorionic villi mesenchymal stem cells (e.g.
  • the placenta-derived adherent cell exosomes described herein comprise CD73 at a level two-fold, three-fold, four-fold, five-fold, six-fold, seven- fold, eight- fold, nine-fold, or ten- fold higher than exosomes derived from chorionic villi mesenchymal stem cells (e.g.
  • the placenta-derived adherent cell exosomes described herein comprise CD73 at a level two-fold to three-fold, three-fold to four-fold, four-fold to five-fold, five-fold to six-fold, six-fold to sevenfold, seven-fold to eight-fold, eight- fold to nine-fold or nine-fold to ten- fold higher than exosomes derived from chorionic villi mesenchymal stem cells (e.g.
  • the placenta-derived adherent cell exosomes described herein comprise CD 82 at a level two-fold, three-fold, four-fold, five-fold, six-fold, seven- fold, eight- fold, nine-fold, or ten- fold higher than exosomes derived from chorionic villi mesenchymal stem cells (e.g., the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451) or pre-adipocyte mesenchymal stem cells, wherein CD82 content is measured under the same experimental conditions (e.g., by flow cytometry, for example, by FACS), wherein the exosomes are harvested under like conditions, and wherein the cells of origin are grown under like conditions.
  • chorionic villi mesenchymal stem cells e.g., the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS
  • the placenta-derived adherent cell exosomes described herein comprise CD82at a level two-fold to three-fold, threefold to four-fold, four-fold to five-fold, five-fold to six-fold, six-fold to seven-fold, seven-fold to eight- fold, eight- fold to nine-fold or nine-fold to ten- fold higher than exosomes derived from chorionic villi mesenchymal stem cells (e.g.
  • the placenta-derived adherent cell exosomes described herein comprise CD82 at a level two-fold, three-fold, four-fold, five-fold, six-fold, seven- fold, eight- fold, nine-fold, or ten- fold higher than exosomes derived from chorionic villi mesenchymal stem cells (e.g.
  • the placenta-derived adherent cell exosomes described herein comprise CD82at a level two-fold to three-fold, three-fold to four-fold, four-fold to five-fold, five-fold to six-fold, six-fold to sevenfold, seven-fold to eight-fold, eight- fold to nine-fold or nine-fold to ten- fold higher than exosomes derived from chorionic villi mesenchymal stem cells (e.g.
  • the placenta-derived adherent cell exosomes described herein comprise CD90 at a level two-fold, three-fold, four-fold, five-fold, six-fold, seven-fold, eight- fold, nine-fold, or ten- fold higher than exosomes derived from chorionic villi mesenchymal stem cells (e.g., the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451) or pre-adipocyte mesenchymal stem cells, wherein CD90 content is measured under the same experimental conditions (e.g., by flow cytometry, for example, by FACS), wherein the exosomes are harvested under like conditions, and wherein the cells of origin are grown under like conditions.
  • chorionic villi mesenchymal stem cells e.g., the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE
  • the placenta-derived adherent cell exosomes described herein comprise CD90 at a level two-fold to three-fold, threefold to four-fold, four-fold to five-fold, five-fold to six-fold, six-fold to seven-fold, seven-fold to eight- fold, eight- fold to nine-fold or nine-fold to ten- fold higher than exosomes derived from chorionic villi mesenchymal stem cells (e.g.
  • flow cytometry for example, by FACS
  • the placenta-derived adherent cell exosomes described herein comprise CD90 at a level two-fold, three-fold, four-fold, five-fold, six-fold, seven- fold, eight- fold, nine-fold, or ten- fold higher than exosomes derived from chorionic villi mesenchymal stem cells (e.g.
  • the placenta-derived adherent cell exosomes described herein comprise CD90 at a level two-fold to three-fold, three-fold to four-fold, four-fold to five-fold, five-fold to six-fold, six-fold to sevenfold, seven-fold to eight-fold, eight- fold to nine-fold or nine-fold to ten- fold higher than exosomes derived from chorionic villi mesenchymal stem cells (e.g.
  • placenta-derived adherent cell exosomes described herein comprise CD 142 at a level two-fold, three-fold, four- fold, five-fold, six-fold, seven- fold, eight- fold, nine-fold, or ten- fold higher than exosomes derived from chorionic villi mesenchymal stem cells (e.g., the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451) or pre-adipocyte mesenchymal stem cells, wherein CD142 content is measured under the same experimental conditions (e.g., by flow cytometry, for example, by FACS), wherein the exosomes are harvested under like conditions, and wherein the cells of origin are grown under like conditions.
  • chorionic villi mesenchymal stem cells e.g., the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE
  • the placenta-derived adherent cell exosomes described herein comprise CD 142 at a level two-fold to three-fold, threefold to four-fold, four-fold to five-fold, five-fold to six-fold, six-fold to seven-fold, seven-fold to eight- fold, eight- fold to nine-fold or nine-fold to ten- fold higher than exosomes derived from chorionic villi mesenchymal stem cells (e.g.
  • placenta-derived adherent cell exosomes described herein comprise CD 142 at a level two-fold, three-fold, four-fold, five-fold, six-fold, seven- fold, eight- fold, nine-fold, or ten- fold higher than exosomes derived from chorionic villi mesenchymal stem cells (e.g.
  • the placenta-derived adherent cell exosomes described herein comprise CD 142 at a level two-fold to three-fold, three-fold to four-fold, four-fold to five-fold, five-fold to six-fold, six-fold to sevenfold, seven-fold to eight-fold, eight- fold to nine-fold or nine-fold to ten- fold higher than exosomes derived from chorionic villi mesenchymal stem cells (e.g.
  • the placenta-derived adherent cell exosomes described herein comprise CD49c, CD90, CD 142 and CD82 at a level two-fold, three-fold, fourfold, five-fold, six-fold, seven- fold, eight- fold, nine-fold, or ten-fold higher than exosomes derived from chorionic villi mesenchymal stem cells (e.g., the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451) or pre-adipocyte mesenchymal stem cells, wherein CD49c, CD90, CD 142 and CD82 content is measured under the same experimental conditions (e.g., by flow cytometry, for example, by FACS), wherein the exosomes are harvested under like conditions, and wherein the cells of origin are grown under like conditions.
  • chorionic villi mesenchymal stem cells e.g., the chorionic villi me
  • the placenta-derived adherent cell exosomes described herein comprise CD49c, CD90, CD 142 and CD82 at a level two-fold to three-fold, three-fold to four- fold, four-fold to five-fold, five-fold to six-fold, six-fold to seven- fold, sevenfold to eight- fold, eight-fold to nine-fold or nine-fold to ten- fold higher than exosomes derived from chorionic villi mesenchymal stem cells (e.g.
  • the placenta-derived adherent cell exosomes described herein comprise CD49c, CD90, CD 142 and CD82 at a level two-fold, three-fold, fourfold, five-fold, six-fold, seven- fold, eight- fold, nine-fold, or ten-fold higher than exosomes derived from chorionic villi mesenchymal stem cells (e.g., the chorionic villi mesenchymal stem cells described in Salomon et al., 2013, PLOS ONE, 8:7, e68451) or pre-adipocyte mesenchymal stem cells, wherein CD49c, CD90, CD 142 and CD82 content is measured under the same experimental conditions (e.g., by flow cytometry, for example, by FACS), and wherein the same
  • the placenta-derived adherent cell exosomes described herein comprise CD49c, CD90, CD 142 and CD 82 at a level two-fold to three-fold, three-fold to four- fold, four- fold to five-fold, five-fold to six-fold, six-fold to seven- fold, seven- fold to eight- fold, eight- fold to nine-fold or nine-fold to ten- fold higher than exosomes derived from chorionic villi mesenchymal stem cells (e.g., the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451) or pre-adipocyte mesenchymal stem cells, wherein CD49c, CD90, CD142 and CD82 content is measured under the same experimental conditions (e.g., by flow cytometry, for example, by FACS), and wherein the same number and/or mass of exosomes is used for each sample.
  • placenta-derived adherent cell exosomes described herein may additionally comprise certain other exosomal markers.
  • the placenta-derived adherent cell exosomes described herein comprise exosomal surface markers FLOT1, ALIX, ANXA5, and TSG101 in addition to any marker combination described herein.
  • disclosed herein are compositions of placenta-derived adherent cell exosomes containing any combination of the above-referenced surface markers.
  • the placenta-derived adherent cell exosomes described herein contain one or more nucleic acid molecules, e.g., one or more non-coding RNA molecules.
  • the placenta-derived adherent cell exosomes provided herein comprise microRNAs (miRNAs).
  • miRNAs are 17-22 nucleotide (nt) non-coding RNAs that modulate a broad range of cellular functions and are implicated in diseases and metabolic regulation.
  • Methods of detecting miRNA levels are well known in the art, e.g., real-time PCR (RT-PCR), for example, Taqman assay.
  • the placenta-derived adherent cell exosomes contain miRNAs that, when subjected to RT-PCR and compared to a control RNA, are contained at a level 1.1, 2, 5, 10, 100, 500, 600, 700, 800, 900, 1000, 1100 or 1200 times higher than the same miRNA in chorionic villi mesenchymal stem cells, or between 1.1 and 2, 2 and 5, 2 and 10, 5 and 10, 10 and 100, 100 and 500, 500 and 600, 600 and 700, 700 and 800, 800 and 900, 900 and 1000, 1000 and 1100, or 1100 and 1200 times higher than the same miRNA in chorionic villi mesenchymal stem cells.
  • the placenta-derived adherent cell exosomes described herein contain detectable levels of one, two, three, four or more of the following miRNAs: miR-218-5p, miR-133b, miR-422a, miR-564, miR-16-5p, let-7a, miR-92, miR-142-3p, miR-451, miR-124-5p, miR-223-3p, miR-630, miR-296-5p, let-7b-3p and let-7d-3p.
  • the placenta- derived adherent cell exosomes described herein comprise detectable levels of miR-218-5p.
  • the placenta-derived adherent cell exosomes described herein comprise detectable levels of miR-133b. In another embodiment, the placenta-derived adherent cell exosomes described herein comprise detectable levels of miR-422a. In another embodiment, the placenta-derived adherent cell exosomes described herein comprise detectable levels of miR- 564. In another embodiment, the placenta-derived adherent cell exosomes described herein comprise detectable levels of miR-16-5p. In another embodiment, the placenta-derived adherent cell exosomes described herein comprise detectable levels of let-7a.
  • the placenta-derived adherent cell exosomes described herein comprise detectable levels of miR-92. In another embodiment, the placenta-derived adherent cell exosomes described herein comprise detectable levels of miR-142-3p. In another embodiment, the placenta-derived adherent cell exosomes described herein comprise detectable levels of miR-451. In another embodiment, the placenta-derived adherent cell exosomes described herein comprise detectable levels of miR- 124-5p. In another embodiment, the placenta-derived adherent cell exosomes described herein comprise detectable levels of miR-223-3p.
  • the placenta-derived adherent cell exosomes described herein comprise detectable levels of miR-630. In another embodiment, the placenta-derived adherent cell exosomes described herein comprise detectable levels of miR-296-5p. In another embodiment, the placenta-derived adherent cell exosomes described herein comprise detectable levels of let-7b-3p. In another embodiment, the placenta- derived adherent cell exosomes described herein comprise detectable levels of let-7d-3p.
  • the placenta-derived adherent cell exosomes described herein comprise detectable levels of miR-218-5p and additionally comprise detectable levels of one or more of the miRNAs selected from the group of miR-133b, miR-422a, miR-564, miR-16-5p, let- 7a, miR-92, miR-142-3p, miR-451, miR-124-5p, miR-223-3p, miR-630, miR-296-5p, let-7b-3p and let-7d-3p.
  • the placenta-derived adherent cell exosomes described herein comprise detectable levels of miR-133b and additionally comprise detectable levels of one or more of the miRNAs selected from the group of miR-218-5p, miR-422a, miR-564, miR-16-5p, let-7a, miR-92, miR-142-3p, miR-451, miR-124-5p, miR-223-3p, miR-630, miR-296-5p, let-7b- 3p and let-7d-3p.
  • the placenta-derived adherent cell exosomes described herein comprise detectable levels of miR-422a and additionally comprise detectable levels of one or more of the miRNAs selected from the group of miR-218-5p, miR-133b, miR-564, miR-16-5p, let-7a, miR-92, miR-142-3p, miR-451, miR-124-5p, miR-223-3p, miR-630, miR-296-5p, let-7b- 3p and let-7d-3p.
  • the placenta-derived adherent cell exosomes described herein comprise detectable levels of miR-564 and additionally comprise detectable levels of one or more of the miRNAs selected from the group of miR-218-5p, miR-133b, miR-422a, miR-16-5p, let-7a, miR-92, miR-142-3p, miR-451, miR-124-5p, miR-223-3p, miR-630, miR-296-5p, let-7b- 3p and let-7d-3p.
  • the placenta-derived adherent cell exosomes described herein comprise detectable levels of miR-16-5p and additionally comprise detectable levels of one or more of the miRNAs selected from the group of miR-218-5p, miR-133b, miR-422a, miR-564, let-7a, miR-92, miR-142-3p, miR-451, miR-124-5p, miR-223-3p, miR-630, miR-296-5p, let-7b- 3p and let-7d-3p.
  • the placenta-derived adherent cell exosomes described herein comprise detectable levels of let-7a and additionally comprise detectable levels of one or more of the miRNAs selected from the group of miR-218-5p, miR-133b, miR-422a, miR-564, miR-16- 5p, miR-92, miR-142-3p, miR-451, miR-124-5p, miR-223-3p, miR-630, miR-296-5p, let-7b-3p and let-7d-3p.
  • the placenta-derived adherent cell exosomes described herein comprise detectable levels of miR-92 and additionally comprise detectable levels of one or more of the miRNAs selected from the group of miR-218-5p, miR-133b, miR-422a, miR-564, miR- 16-5p, let-7a, miR-142-3p, miR-451, miR-124-5p, miR-223-3p, miR-630, miR-296-5p, let-7b-3p and let-7d-3p.
  • the placenta-derived adherent cell exosomes described herein comprise detectable levels of miR-142-3p and additionally comprise detectable levels of one or more of the miRNAs selected from the group of miR-218-5p, miR-133b, miR-422a, miR-564, miR-16-5p, let-7a, miR-92, miR-451, miR-124-5p, miR-223-3p, miR-630, miR-296-5p, let-7b- 3p and let-7d-3p.
  • the placenta-derived adherent cell exosomes described herein comprise detectable levels of miR-451 and additionally comprise detectable levels of one or more of the miRNAs selected from the group of miR-218-5p, miR-133b, miR-422a, miR-564, miR-16-5p, let-7a, miR-92, miR-142-3p, miR-124-5p, miR-223-3p, miR-630, miR-296-5p, let- 7b-3p and let-7d-3p.
  • the placenta-derived adherent cell exosomes described herein comprise detectable levels of miR-124-5p and additionally comprise detectable levels of one or more of the miRNAs selected from the group of miR-218-5p, miR-133b, miR-422a, miR-564, miR-16-5p, let-7a, miR-92, miR-142-3p, miR-451, miR-223-3p, miR-630, miR-296-5p, let-7b- 3p and let-7d-3p.
  • the placenta-derived adherent cell exosomes described herein comprise detectable levels of miR-223-3p and additionally comprise detectable levels of one or more of the miRNAs selected from the group of miR-218-5p, miR-133b, miR-422a, miR-564, miR-16-5p, let-7a, miR-92, miR-142-3p, miR-451 , miR-124-5p, miR-630, miR-296-5p, let-7b- 3p and let-7d-3p.
  • the placenta-derived adherent cell exosomes described herein comprise detectable levels of miR-630 and additionally comprise detectable levels of one or more of the miRNAs selected from the group of miR-218-5p, miR-133b, miR-422a, miR-564, miR-16-5p, let-7a, miR-92, miR-142-3p, miR-451 , miR-124-5p, miR-223-3p, miR-296-5p, let- 7b-3p and let-7d-3p.
  • the placenta-derived adherent cell exosomes described herein comprise detectable levels of miR-296-5p and additionally comprise detectable levels of one or more of the miRNAs selected from the group of miR-218-5p, miR-133b, miR-422a, miR-564, miR-16-5p, let-7a, miR-92, miR-142-3p, miR-451 , miR-124-5p, miR-223-3p, miR-630, let-7b- 3p and let-7d-3p.
  • the placenta-derived adherent cell exosomes described herein comprise detectable levels of let-7b-3p and additionally comprise detectable levels of one or more of the miRNAs selected from the group of miR-218-5p, miR-133b, miR-422a, miR-564, miR-16-5p, let-7a, miR-92, miR-142-3p, miR-451 , miR-124-5p, miR-223-3p, miR-630, miR- 296-5p and let-7d-3p.
  • the placenta-derived adherent cell exosomes described herein comprise detectable levels of let-7d-3p and additionally comprise detectable levels of one or more of the miRNAs selected from the group of miR-218-5p, miR-133b, miR-422a, miR-564, miR-16-5p, let-7a, miR-92, miR-142-3p, miR-451 , miR-124-5p, miR-223-3p, miR-630, miR- 296-5p and let-7b-3p.
  • the placenta-derived adherent cell exosomes described herein comprise miR-218-5p, miR-133b, miR-422a, miR-564, miR-16-5p, let-7a, miR-92, miR- 142-3p, miR-451 , miR-124-5p, miR-223-3p, miR-630, miR-296-5p, let-7b-3p and let-7d-3p.
  • the placenta-derived adherent cell exosomes described herein can be distinguished from exosomes from other cells (e.g., chorionic villi mesenchymal stem cells, e.g., the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451) based on the miRNA they comprise.
  • other cells e.g., chorionic villi mesenchymal stem cells, e.g., the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451
  • the placenta-derived adherent cell exosomes described herein comprise miR-133b at a level at least two-fold higher when compared to exosomes from chorionic villi mesenchymal stem cells (e.g. , the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451) when the exosomes and the cells from which they are derived are treated under like conditions.
  • chorionic villi mesenchymal stem cells e.g. , the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451
  • the placenta-derived adherent cell exosomes described herein comprise miR-422a at a level at least two-fold higher as compared to exosomes from chorionic villi mesenchymal stem cells (e.g. , the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451) when the exosomes and the cells from which they are derived are treated by like methods.
  • chorionic villi mesenchymal stem cells e.g. , the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451
  • the placenta-derived adherent cell exosomes described herein comprise miR-16-5p at a level at least two-fold higher as compared to exosomes from chorionic villi mesenchymal stem cells (e.g. , the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451) when the exosomes and the cells from which they are derived are treated by like methods.
  • chorionic villi mesenchymal stem cells e.g. , the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451
  • the placenta-derived adherent cell exosomes described herein comprise let-7a at a level at least two-fold higher as compared to exosomes from chorionic villi mesenchymal stem cells (e.g., the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451) when the exosomes and the cells from which they are derived are treated by like methods.
  • chorionic villi mesenchymal stem cells e.g., the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451
  • the placenta-derived adherent cell exosomes described herein comprise miR-92 at a level at least two-fold higher as compared to exosomes from chorionic villi mesenchymal stem cells (e.g., the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451) when the exosomes and the cells from which they are derived are treated by like methods.
  • chorionic villi mesenchymal stem cells e.g., the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451
  • the placenta-derived adherent cell exosomes described herein comprise miR-142-3p at a level at least two-fold higher as compared to exosomes from chorionic villi mesenchymal stem cells (e.g. , the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451) when the exosomes and the cells from which they are derived are treated by like methods.
  • chorionic villi mesenchymal stem cells e.g. , the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451
  • the placenta-derived adherent cell exosomes described herein comprise miR-451 at a level at least two-fold higher as compared to exosomes from chorionic villi mesenchymal stem cells (e.g. , the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451) when the exosomes and the cells from which they are derived are treated by like methods.
  • chorionic villi mesenchymal stem cells e.g. , the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451
  • the placenta-derived adherent cell exosomes described herein comprise miR-124-5p at a level at least two-fold higher as compared to exosomes from chorionic villi mesenchymal stem cells (e.g. , the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451) when the exosomes and the cells from which they are derived are treated by like methods.
  • chorionic villi mesenchymal stem cells e.g. , the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451
  • the placenta-derived adherent cell exosomes described herein comprise miR-223-3p at a level at least two-fold higher as compared to exosomes from chorionic villi mesenchymal stem cells (e.g. , the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451) when the exosomes and the cells from which they are derived are treated by like methods.
  • chorionic villi mesenchymal stem cells e.g. , the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451
  • the placenta-derived adherent cell exosomes described herein comprise miR-630 at a level at least two-fold higher as compared to exosomes from chorionic villi mesenchymal stem cells (e.g. , the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451) when the exosomes and the cells from which they are derived are treated by like methods.
  • chorionic villi mesenchymal stem cells e.g. , the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451
  • the placenta-derived adherent cell exosomes described herein comprise miR-296-5p at a level at least two-fold higher as compared to exosomes from chorionic villi mesenchymal stem cells (e.g. , the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451) when the exosomes and the cells from which they are derived are treated by like methods.
  • chorionic villi mesenchymal stem cells e.g. , the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451
  • the placenta-derived adherent cell exosomes described herein comprise let-7b-3p at a level at least two-fold higher as compared to exosomes from chorionic villi mesenchymal stem cells (e.g. , the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451) when the exosomes and the cells from which they are derived are treated by like methods.
  • chorionic villi mesenchymal stem cells e.g. , the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451
  • the placenta-derived adherent cell exosomes described herein comprise let-7d-3p at a level at least two-fold higher as compared to exosomes from chorionic villi mesenchymal stem cells (e.g. , the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451) when the exosomes and the cells from which they are derived are treated by like methods.
  • chorionic villi mesenchymal stem cells e.g. , the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451
  • the placenta-derived adherent cell exosomes described herein comprise miR-133b and additionally one or more miRNA selected from the group of miR-422a, miR-16-5p, let-7a, miR-92, miR-142-3p, miR-451 , miR-223-3p, miR-630, miR-296-5p, let-7b- 3p and let-7d-3p at a level at least two-fold higher as compared to exosomes from chorionic villi mesenchymal stem cells (e.g., the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451) when the exosomes and the cells from which they are derived are treated by like methods.
  • chorionic villi mesenchymal stem cells e.g., the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE,
  • the placenta-derived adherent cell exosomes described herein comprise miR-422a and additionally one or more miRNA selected from the group of miR-133b, miR-16-5p, let-7a, miR-92, miR-142-3p, miR-451 , miR-223-3p, miR-630, miR-296-5p, let-7b- 3p and let-7d-3p at a level at least two-fold higher as compared to exosomes from chorionic villi mesenchymal stem cells (e.g., the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451) when the exosomes and the cells from which they are derived are treated by like methods.
  • chorionic villi mesenchymal stem cells e.g., the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE,
  • the placenta-derived adherent cell exosomes described herein comprise miR-16-5p and additionally one or more miRNA selected from the group of miR-133b, miR-422a, let-7a, miR-92, miR-142-3p, miR-451 , miR-223-3p, miR-630, miR-296-5p, let-7b-3p and let-7d-3p at a level at least two-fold higher as compared to exosomes from chorionic villi mesenchymal stem cells (e.g., the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451) when the exosomes and the cells from which they are derived are treated by like methods.
  • chorionic villi mesenchymal stem cells e.g., the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8
  • the placenta-derived adherent cell exosomes described herein comprise let-7a and additionally one or more miRNA selected from the group of miR-133b, miR-422a, miR-16-5p, miR-92, miR-142-3p, miR-451 , miR-223-3p, miR-630, miR-296-5p, let- 7b-3p and let-7d-3p at a level at least two-fold higher as compared to exosomes from chorionic villi mesenchymal stem cells (e.g. , the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451) when the exosomes and the cells from which they are derived are treated by like methods.
  • chorionic villi mesenchymal stem cells e.g. , the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS
  • the placenta-derived adherent cell exosomes described herein comprise miR-92 and additionally one or more miRNA selected from the group of miR-133b, miR-422a, miR-16-5p, let-7a, miR-142-3p, miR-451 , miR-223-3p, miR-630, miR-296-5p, let- 7b-3p and let-7d-3p at a level at least two-fold higher as compared to exosomes from chorionic villi mesenchymal stem cells (e.g. , the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451) when the exosomes and the cells from which they are derived are treated by like methods.
  • chorionic villi mesenchymal stem cells e.g. , the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS
  • the placenta-derived adherent cell exosomes described herein comprise miR-142-3p and additionally one or more miRNA selected from the group of miR- 133b, miR-422a, miR-16-5p, let-7a, miR-92, miR-451 , miR-223-3p, miR-630, miR-296-5p, let- 7b-3p and let-7d-3p at a level at least two-fold higher as compared to exosomes from chorionic villi mesenchymal stem cells (e.g. , the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451) when the exosomes and the cells from which they are derived are treated by like methods.
  • chorionic villi mesenchymal stem cells e.g. , the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS
  • the placenta-derived adherent cell exosomes described herein comprise miR-451 and additionally one or more miRNA selected from the group of miR-133b, miR-422a, miR-16-5p, let-7a, miR-92, miR-142-3p, miR-223-3p, miR-630, miR-296-5p, let-7b- 3p and let-7d-3p at least two-fold higher as compared to exosomes from chorionic villi mesenchymal stem cells (e.g., the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451) when the exosomes and the cells from which they are derived are treated by like methods.
  • chorionic villi mesenchymal stem cells e.g., the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7,
  • the placenta-derived adherent cell exosomes described herein comprise miR-223-3p and additionally one or more miRNA selected from the group of miR- 133b, miR-422a, miR-16-5p, let-7a, miR-92, miR-142-3p, miR-451 , miR-630, miR-296-5p, let- 7b-3p and let-7d-3p at a level at least two-fold higher as compared to exosomes from chorionic villi mesenchymal stem cells (e.g. , the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451) when the exosomes and the cells from which they are derived are treated by like methods.
  • chorionic villi mesenchymal stem cells e.g. , the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS
  • the placenta-derived adherent cell exosomes described herein comprise miR-630 and additionally one or more miRNA selected from the group of miR-133b, miR-422a, miR-16-5p, let-7a, miR-92, miR-142-3p, miR-451 , miR-223-3p, miR-296-5p, let-7b- 3p and let-7d-3p at a level at least two-fold higher as compared to exosomes from chorionic villi mesenchymal stem cells (e.g., the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451) when the exosomes and the cells from which they are derived are treated by like methods.
  • chorionic villi mesenchymal stem cells e.g., the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE,
  • the placenta-derived adherent cell exosomes described herein comprise miR-296-5p and additionally one or more miRNA selected from the group of miR- 133b, miR-422a, miR-16-5p, let-7a, miR-92, miR-142-3p, miR-451 , miR-223-3p, miR-630, let- 7b-3p and let-7d-3p at a level at least two-fold higher as compared to exosomes from chorionic villi mesenchymal stem cells (e.g. , the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451) when the exosomes and the cells from which they are derived are treated by like methods.
  • chorionic villi mesenchymal stem cells e.g. , the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS
  • the placenta-derived adherent cell exosomes described herein comprise let-7b-3p and additionally one or more miRNA selected from the group of miR-133b, miR-422a, miR-16-5p, let-7a, miR-92, miR-142-3p, miR-451 , miR-223-3p, miR-630, miR-296- 5p and let-7d-3p at a level at least two-fold higher as compared to exosomes from chorionic villi mesenchymal stem cells (e.g., the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451) when the exosomes and the cells from which they are derived are treated by like methods.
  • chorionic villi mesenchymal stem cells e.g., the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE,
  • the placenta-derived adherent cell exosomes described herein comprise let-7d-3p and additionally one or more miRNA selected from the group of miR-133b, miR-422a, miR-16-5p, let-7a, miR-92, miR-142-3p, miR-451 , miR-223-3p, miR-630, miR-296- 5p and let-7b-3p at a level at least two-fold higher as compared to exosomes from chorionic villi mesenchymal stem cells (e.g., the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451) when the exosomes and the cells from which they are derived are treated by like methods.
  • chorionic villi mesenchymal stem cells e.g., the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE,
  • the placenta-derived adherent cell exosomes described herein comprise miR-133b, miR-422a, miR-16-5p, let-7a, miR-92, miR-142-3p, miR-451, miR-223-3p, miR-630, miR-296-5p, let-7b-3p and let-7d-3p or a combination of any of the foregoing at a level at least two-fold higher when compared to exosomes from chorionic villi mesenchymal stem cells (e.g., the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:7, e68451) when the exosomes and the cells from which they are derived are treated by like conditions.
  • chorionic villi mesenchymal stem cells e.g., the chorionic villi mesenchymal stem cells described in Salomon et al, 2013, PLOS ONE, 8:
  • the placenta-derived adherent cell exosomes described herein contain one or more proteins that promote angiogenesis.
  • Methods of detecting angiogenic protein levels are well known in the art, e.g. , using an ELIS A-based method, for example, AngioSecretome Milliplex (Millipore).
  • ELIS A-based method for example, AngioSecretome Milliplex (Millipore).
  • the presence and relative levels of angiogenic proteins associated with the placenta-derived adherent cell exosomes described herein is determined by the method described in Section 6.2.4.3, infra.
  • the placenta-derived adherent cell exosomes described herein contain one or more angiogenic proteins selected from the group of Endoglin, Leptin,
  • the placenta-derived adherent cell exosomes described herein contain one or more angiogenic proteins selected from the group of Endoglin, Leptin, Angiopoietin-2, G-CSF, Follistatin, FGF-2, HGF, VEGF-A, IL-8 and EGF at a level higher than culture medium lacking exosomes.
  • said angiogenic proteins are present in culture medium at a concentration of greater than 10 pg/ml, 50 pg/ml, 100 pg/ml, 500 pg/ml, 1,000 pg/ml, 2,000 pg/ml, 4,000 pg/ml, 6,000 pg/ml, 8,000 pg/ml, 10,000 pg/ml, 12,000 pg/ml, 14,000 pg/ml, 16,000 pg/ml, 18,000 pg/ml, 20,000 pg/ml, 25,000 pg/ml, 30,000 pg/ml, 35,000 pg/ml, 40,000 pg/ml, 45,000 pg/ml, or 50,000 pg/ml or higher.
  • said angiogenic proteins are present in culture medium at a concentration of 10 pg/ml to 50 pg/ml, 50 pg/ml to 100 pg/ml, 100 pg/ml to 500 pg/ml, 500 pg/ml to 1,000 pg/ml, 1,000 pg/ml to 2,000 pg/ml, 2,000 pg/ml to 4,000 pg/ml, 4,000 pg/ml to 6,000 pg/ml, 6,000 pg/ml to 8,000 pg/ml, 8,000 pg/ml to 10,000 pg/ml, 10,000 pg/ml 12,000 pg/ml, 12,000 pg/ml to 14,000 pg/ml, 14,000 pg/ml to 16,000 pg/ml, 16,000 pg/ml to 18,000 pg/ml, 18,000 pg/ml to 20,000 pg/m
  • the placenta-derived adherent cell exosomes described herein are about 50nm to 150 nm in diameter. In certain embodiments, the placenta-derived adherent cell exosomes described herein are about 70nm to 150nm in diameter, about lOOnm to 150nm in diameter, or about 130nm to 145nm in diameter, as determined by methods known in the art (e.g., electron microscopy and Nanoparticle Tracking Assay). In certain embodiments, the placenta-derived adherent cell exosomes described herein can be distinguished from cellular and/or non-cellular debris on the basis of their size. In certain embodiments, the exosomes described herein can be distinguished by their shape, for example, the exosomes described herein are cup-shaped when viewed by imaging techniques known in the art (e.g., electron microscopy).
  • the placenta-derived adherent cell exosomes described herein can be identified on the basis of their molecular composition (e.g., surface marker proteins or miR A molecules). See Section 5.1.1.
  • the placenta-derived adherent cell exosomes described herein can be distinguished from other exosomes (i.e., non-placenta- derived adherent cell exosomes) based their molecular profile (e.g., the surface marker proteins and/or miRNA molecules they comprise). See Section 5.1.1.
  • placenta-derived adherent cell exosomes described herein are derived from placenta-derived adherent cells (e.g., the placenta-derived adherent cells disclosed in U.S. Patent Nos. 7,468,276; 8,057,788 and 8,202,703, the disclosures of which are hereby incorporated by reference in their entireties).
  • the placenta-derived adherent cell exosomes described herein are derived from CD34 , CD 10 , CD 105 and CD200 placenta-derived adherent cells.
  • the placenta-derived adherent cell exosomes described herein are derived from placenta-derived adherent cells that express one or more genes at a level at least two-fold higher than bone marrow-derived mesenchymal stem cells, wherein said genes are selected from the group consisting of ACTG2, ADARB1, AMIG02, ARTS-1, B4GALT6, BCHE, Cl lorf9, CD200, COL4A1, COL4A2, CPA4, DMD, DSC3, DSG2,
  • ELOVL2, F2RL1, FIJ10781 GATA6, GPR126, GPRC5B, HLA-G, ICAM1, IER3, IGFBP7, ILIA, IL6, IL18, K T18, K T8, LIPG, LRAP, MATN2, MEST, NFE2L3, NUAK1, PCDH7, PDLIM3, PJP2, RTN1, SERPINB9, ST3GAL6, ST6GALNAC5, SLC12A8, TCF21, TGFB2, VTN, and ZC3H12A.
  • the placenta-derived adherent cells from which the exosomes described herein are derived express one or more genes at a level at least two-fold higher than bone marrow-derived mesenchymal stem cells, wherein said one or more genes are one or more of LOVL2, ST3GAL6, ST6GALNAC5, and/or SLC12A8.
  • the placenta-derived adherent cells from which the exosomes provided herein are derived express one or more genes at a level at least two-fold higher than bone marrow-derived mesenchymal stem cells, wherein said one or more genes are one or more of CPA4, TCF21, VTN, B4GALT6, FLJ 10781 , and/or NUAK1.
  • the placenta-derived adherent cell exosomes described herein are obtained from placenta-derived adherent cells grown in culture, e.g., placenta-derived adherent cells that have adhered to a tissue culture substrate, or from placenta-derived adherent cells that have administered to a living organism ⁇ e.g., a mammal, e.g., a human).
  • the cells are cultured in the presence of serum.
  • the cells are cultured in the absence of serum.
  • the placenta-derived adherent cells from which the placenta- derived adherent cell exosomes provided herein are derived are substantially fetal in origin, e.g., the placenta-derived adherent cells are about or at least 90%, 95%, 99% or 100% fetal in origin.
  • the placenta-derived adherent cells from which the placenta-derived adherent cell exosomes provided herein are derived are of mixed origin, e.g., the placenta- derived adherent cells are both fetal and maternal in origin.
  • the placenta-derived adherent cells from which the placenta- derived adherent cell exosomes provided herein are derived have been passaged prior to isolation of exosomes from the placenta-derived adherent cells.
  • the placenta- derived adherent cells from which the placenta-derived adherent cell exosomes provided herein are derived have been passaged about or at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, or 20 times prior to isolation of exosomes from the placenta-derived adherent cells.
  • the exosomes provided herein are collected from placenta-derived adherent cells that have been cultured in vitro for 6 passages. In certain embodiments, the exosomes provided herein are collected from placenta-derived adherent cells plated at passage 6, and collected from culture supernatant at passage 7.
  • the placenta-derived adherent cells from which the placenta- derived adherent cell exosomes provided herein are derived have been expanded prior to isolation of exosomes from the placenta-derived adherent cells.
  • the placenta-derived adherent cells from which the placenta-derived adherent cell exosomes provided herein are derived have been expanded for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38 or 40 population doublings, or more, prior to isolation of exosomes from the placenta-derived adherent cells.
  • the placenta-derived adherent cells from which the placenta-derived adherent cell exosomes provided herein are derived are not chorionic villi mesenchymal stem cells and/or do not comprise chorionic villi mesenchymal stem cells, e.g., the placenta-derived adherent cells from which the placenta-derived adherent cell exosomes provided herein are derived are not the chorionic villi mesenchymal stem cells described in Salomon et ah, 2013, PLOS ONE, 8:7, e68451.
  • the source from which the placenta-derived adherent cells are derived does not contain chorionic villi.
  • the placenta-derived adherent cell exosomes described herein can be produced from, e.g., the placenta-derived adherent cells described in Section 5.1.3.
  • the culture of such placenta-derived adherent cells results in the deposition of exosomes into the culture medium, wherein said exosomes may be isolated from the culture medium using techniques described herein and known in the art.
  • the isolation of placenta-derived adherent cell exosomes described herein may be accomplished based on specific surface marker molecules associated with the placenta-derived adherent cell exosomes, using size filtration, using density- dependent centrifugation, and by using other methods known in the art.
  • isolation of the placenta-derived adherent cell exosomes described herein can combine two or more techniques to substantially purify exosome populations from contaminating cellular and non-cellular material present in culture medium.
  • the placenta-derived adherent cell exosomes described herein are separated from other components of cell culture medium using ultracentrifugation.
  • culture medium collected from cultures of placenta-derived adherent cells is isolated and centrifuged at high speed (e.g., 100,000xg) for a time sufficient to separate placenta-derived adherent cell exosomes from cellular and non-cellular materials present in the culture medium.
  • placenta-derived adherent cells are cultured in the presence of serum (e.g.
  • placenta-derived adherent cells are cultured in the absence of serum (e.g., fetal bovine serum) prior to collecting culture medium for the isolation of placenta-derived adherent cell exosomes.
  • serum e.g., fetal bovine serum
  • culture medium collected from cultures of placenta-derived adherent cells is isolated and centrifuged according to the method of Example 1, infra.
  • placenta-derived adherent cell exosomes described herein can be isolated and/or purified on the basis of containing one or more surface marker proteins and/or on the basis of lacking one or more surface marker proteins.
  • the placenta-derived adherent cell exosomes described herein can be substantially isolated from non-placenta-derived adherent cell exosomes, or placenta-derived adherent cell exosomes that do not contain the surface markers of interest.
  • one subpopulation of placenta-derived adherent cell exosomes containing a specific combination of surface markers can be isolated from one or more additional populations of exosomes (e.g., placenta-derived adherent cell exosomes) that contain a unique or substantially different combination of surface markers.
  • the placenta-derived adherent cell exosomes described herein can be isolated and/or purified on the basis of any combination of the surface markers described herein. See Section 5.1.1.
  • fluorescence-activated cell sorting is used to separate and/or purify the placenta-derived adherent cell exosomes described herein using antibodies specific to cell surface markers present on the exosomes.
  • FACS fluorescence-activated cell sorting
  • the method of purifying/isolating the placenta-derived adherent cell exosomes described herein comprises contacting a population of exosomes described herein with a solid substrate (e.g. , latex bead) for a time and under conditions sufficient to allow for the creation of a complex between said exosomes and said substrate (e.g., by passive adsorption).
  • a population of exosomes contacted with a solid substrate e.g., latex beads
  • a method described herein e.g., a FACS method described herein.
  • the placenta-derived adherent cell exosomes described herein can be purified and/or isolated using a two-part "sandwich" detection technique.
  • the exosomes in a partially purified or unpurified population are first contacted with a substrate, e.g., a population of beads (e.g., a population of latex beads), that are coated with an antibody specific for a protein that is present on the surface of the placenta-derived adherent cell exosomes described herein.
  • a substrate e.g., a population of beads (e.g., a population of latex beads)
  • an antibody that specifically recognizes CD63 is used to isolate the placenta-derived adherent cell exosomes described herein using such a method.
  • an antibody that specifically recognizes a member of the MHC class II molecule family is used to isolate the placenta-derived adherent cell exosomes described herein using such a method.
  • the exosomes bound to the substrate are contacted by a second molecule specific to a surface marker protein that is present on the surface of the placenta-derived adherent cell exosomes described herein.
  • the surface molecule is a tetraspanin and said antibody is a fluorescently- labeled antibody.
  • the surface molecule is any one of FLOT1, ALIX, ANXA5, TSG101, Annexin V, CD3, CD9, CD10, CDl lb, CD13, CD14, CD19, CD29, CD33, CD44, CD46, CD47, CD49b, CD49c, CD55, CD59, CD63, CD73, CD81, CD90, CD98, CD 105, CD 142, CD 147, CD151, CD 164, CD 166, CD 192, HLA-A, HLA-B, HLA-C, HLA-DR, CD1 lc, CD34, CD49d or CD200.
  • placenta-derived adherent cell exosomes described herein can be isolated and/or purified from common contaminants present in culture medium, including thyroglobulin dimers, thyroglobulin monomers, Immunglobulins (e.g., IgG), bovine serum albumin (BSA),
  • thyroglobulin dimers e.g., IgG
  • thyroglobulin monomers e.g., IgG
  • Immunglobulins e.g., IgG
  • BSA bovine serum albumin
  • the placenta-derived adherent cell exosomes described herein are distinguished in a sample from common culture medium contaminants (e.g., Thyroglobulin, IgG, BSA, Myoglobulin or Uracil) by eluting from a size- exclusion column (e.g., a TSK Guard SWXL column) in fractions collected at 10 minutes to 11 minutes or 11 minutes to 12 minutes after the beginning of fraction collection when said sample is run on an HPLC at a flow rate of 0.5mL/min.
  • a size- exclusion column e.g., a TSK Guard SWXL column
  • the placenta-derived adherent cell exosomes described herein elute in the first detectable peak of a sample collected from a size-exclusion column (e.g. , a TSK Guard S WXL column) after said sample is run on an HPLC at a flow rate of 0.5mL/min.
  • a size-exclusion column e.g. , a TSK Guard S WXL column
  • exosomes can be based on size, e.g., a diameter of about 50-150nm. Exosome size, therefore, allows for the use of techniques such as high-performance liquid chromatography (HPLC) combined with size-exclusion chromatography to isolate substantially pure populations of exosomes and/or to determine the purity of isolated exosome populations.
  • HPLC high-performance liquid chromatography
  • size-exclusion chromatography to isolate substantially pure populations of exosomes and/or to determine the purity of isolated exosome populations.
  • exosomes purified and/or isolated by one of the methods described herein can be subsequently purified by HPLC to remove contaminating macromolecules and other undesired contaminants.
  • Methods of using HPLC and size exclusion chromatography to separate mixed populations of molecules are well-known in the art and rely upon semiporous substrates and ion/pH gradients to differentially separate the various components of mixed populations.
  • the placenta-derived adherent cell exosomes described herein are further purified using a method comprising HPLC (e.g., using an Agilent 1200 Series LC system).
  • said method further comprises using a size-exclusion chromatography column (e.g., TSK Guard SWXL and/or TSK gel G4000, Tosoh Corp.) and a buffer (e.g., 20mM K 2 P0 4 , 150mM NaCl, pH 7.2) at a fixed flow rate (e.g., 0.5ml/min).
  • the placenta-derived adherent cell exosomes described herein have a diameter of 50-150nm.
  • placenta-derived adherent cell exosomes described herein are isolated from a subject (e.g., a mouse or a human) after the introduction of placenta-derived adherent cells or placenta-derived adherent cell exosomes described herein.
  • a subject e.g., a mouse
  • a subject is injected with an antibody specific to a protein contained in or on an exosome described herein, wherein said antibody is coupled to a second high-affinity molecule (e.g., biotin).
  • a second high-affinity molecule e.g., biotin
  • Said subject e.g., a mouse
  • Said subject is additionally injected (e.g., injected intravenously, intraperitoneally, or intramuscularly) with placenta-derived adherent cells and/or isolated placenta-derived adherent cells described herein.
  • placenta-derived adherent cells e.g., injected intravenously, intraperitoneally, or intramuscularly
  • placenta-derived adherent cells e.g., injected intravenously, intraperitoneally, or intramuscularly
  • placenta-derived adherent cells e.g., injected intravenously, intraperitoneally, or intramuscularly
  • blood from the subject e.g., a mouse
  • complexes comprising placenta-derived adherent cell exosomes and antibodies specific to an exosome protein as described herein.
  • Said antibody-exosome complexes can be purified by contacting a substrate (e.g., streptavidin) that is specific to the second high-affinity molecule (e.g. , biotin) coupled to said antibody, and the resulting antibody-exosome complexes can be further purified according to any of the methods described herein.
  • a substrate e.g., streptavidin
  • the second high-affinity molecule e.g. , biotin
  • exosomes isolated from the placenta-derived adherent cell cultures described herein may be quantified to determine total yield.
  • Methods of quantifying exosome yield include Bradford assay, BCA assay, spectrophotometry (e.g. , using a NanoDrop spectrophotometer), direct Enzyme-Linked Immunosorbent Assay (e.g. CD63 / CD9 / CD81 ExoELISA (System Biosciences)), imaging techniques such as Nanoparticle Tracking Analysis (e.g., Nanosight LM10 (Malvern Instruments) or electrical impedence-based
  • exosome yields may be determined either as total amount of material isolated (e.g., mass of exosomal material isolated per cell per day) or as the number of individual particles in a defined volume of culture medium (e.g. exosome particles per mL of culture medium).
  • the placenta-derived adherent cell exosomes described herein may be isolated in accordance with the methods described herein and their yields may be quantified.
  • the placenta-derived adherent cell exosomes described herein are isolated at a concentration of about 0.5-5.0 mg per liter of culture medium (e.g., culture medium with or without serum).
  • the placenta-derived adherent cell exosomes described herein are isolated at a concentration of about 2-3 mg per liter of culture medium (e.g. , culture medium containing serum).
  • the placenta-derived adherent cell exosomes described herein are isolated at a concentration of about 0.5-1.5 mg per liter of culture medium (e.g., culture medium lacking serum).
  • placenta-derived adherent cell exosomes described herein can be preserved, that is, placed under conditions that allow for long-term storage, or conditions that inhibit
  • the placenta-derived adherent cell exosomes described herein can be stored after collection according to a method described above in a composition comprising a buffering agent at an appropriate temperature.
  • the placenta-derived adherent cell exosomes described herein are stored frozen, e.g., at about -20°C or about -80°C.
  • the placenta-derived adherent cell exosomes described herein can be cryopreserved, e.g., in small containers, e.g., ampoules (for example, 2 mL vials). In certain embodiments, the placenta-derived adherent cell exosomes described herein are cryopreserved at a concentration of about 0.1 mg/mL to about 10 mg/mL.
  • the placenta-derived adherent cell exosomes described herein are cryopreserved at a temperature from about -80°C to about -180°C.
  • Cryopreserved exosomes can be transferred to liquid nitrogen prior to thawing for use. In some embodiments, for example, once the ampoules have reached about -90°C, they are transferred to a liquid nitrogen storage area. Cryopreservation can also be done using a controlled-rate freezer.
  • Cryopreserved exosomes can be thawed at a temperature of about 25°C to about 40°C before use.
  • the placenta-derived adherent cell exosomes described herein are stored at temperatures of about 4°C to about 20°C for short periods of time ⁇ e.g. , less than two weeks).
  • compositions e.g., pharmaceutical compositions, comprising the placenta-derived adherent cell exosomes provided herein. See, e.g., Section 5.1.
  • the compositions described herein are useful in the treatment of certain diseases and disorders in subjects ⁇ e.g., human subjects) wherein treatment with exosomes is beneficial. See Section 5.4.1.
  • compositions in addition to comprising the placenta-derived adherent cell exosomes provided herein, the compositions ⁇ e.g. , pharmaceutical compositions) described herein comprise a pharmaceutically acceptable carrier.
  • a pharmaceutically acceptable carrier As used herein, the term
  • pharmaceutically acceptable means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeiae for use in animals, and more particularly in humans.
  • carrier refers to a diluent, adjuvant, excipient, or vehicle with which the pharmaceutical composition is administered. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions.
  • Suitable excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like.
  • suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences” by JP
  • compositions described herein additionally comprise one or more buffers, e.g., saline, phosphate buffered saline (PBS), Dulbecco's PBS (DPBS), and/or sucrose phosphate glutamate buffer.
  • buffers e.g., saline, phosphate buffered saline (PBS), Dulbecco's PBS (DPBS), and/or sucrose phosphate glutamate buffer.
  • the compositions described herein do not comprise buffers.
  • the compositions described herein additionally comprise plasmalyte.
  • compositions described herein additionally comprise one or more salts, e.g., sodium chloride, calcium chloride, sodium phosphate, monosodium glutamate, and aluminum salts ⁇ e.g., aluminum hydroxide, aluminum phosphate, alum (potassium aluminum sulfate), or a mixture of such aluminum salts).
  • the compositions described herein do not comprise salts.
  • compositions described herein can be included in a container, pack, or dispenser together with instructions for administration.
  • compositions described herein can be stored before use, e.g. , the compositions can be stored frozen ⁇ e.g., at about -20°C or at about -80°C); stored in refrigerated conditions ⁇ e.g., at about 4°C); or stored at room temperature.
  • placenta-derived adherent cell exosomes see Section 5.1
  • a composition described herein see Section 5.3
  • the precise dosage of placenta-derived adherent cell exosomes, or compositions thereof, to be administered to a subject will also depend on the route of administration and the seriousness of the disease or condition to be treated, and should be decided according to the judgment of the practitioner and each subject's circumstances.
  • effective dosages may vary depending upon means of administration, target site, physiological state of the patient (including age, body weight, and health), whether the patient is human or an animal, other medications administered, and whether treatment is prophylactic or therapeutic. Treatment dosages are optimally titrated to optimize safety and efficacy.
  • the placenta-derived adherent cell exosomes described herein can be done via various routes known in the art.
  • the placenta-derived adherent cell exosomes described herein, or compositions thereof are administered by local, systemic, subcutaneous, parenteral, intravenous, intramuscular, topical, oral, intradermal, transdermal, or intranasal, administration.
  • said administration is via intravenous injection.
  • said administration is via subcutaneous injection.
  • said administration is topical.
  • the placenta-derived adherent cell exosomes, or compositions thereof are administered in a formulation comprising an extracellular matrix.
  • the placenta-derived adherent cell exosomes, or compositions thereof are administered in combination with one or more additional delivery device, e.g., a stent.
  • the placenta-derived adherent cell exosomes, or compositions thereof are administered locally, e.g. , at or around the site of an area to be treated with said exosomes or compositions, such as hypoxic tissue (e.g., in treatment of ischemic diseases) or draining lymph nodes.
  • the placenta-derived adherent cell exosomes described herein (see Section 5.1), and compositions thereof (see Section 5.3), promote angiogenesis, and, therefore can be used to treat diseases and disorders that benefit from angiogenesis. Accordingly, provided herein are methods of using the placenta-derived adherent cell exosomes described herein, or compositions thereof, to promote angiogenesis in a subject in need thereof.
  • the term "treat” encompasses the cure of, remediation of, improvement of, lessening of the severity of, or reduction in the time course of, a disease, disorder or condition, or any parameter or symptom thereof in a subject.
  • the subject treated in accordance with the methods provided herein is a mammal, e.g., a human.
  • a mammal e.g., a human.
  • provided herein are methods of inducing vascularization or angiogenesis in a subject, said methods comprising administering to the subject the placenta- derived adherent cell exosomes provided herein, or a composition thereof. Accordingly, the methods provided herein can be used to treat diseases and disorders in a subject that that benefit from increased angiogenesis/vascularization.
  • diseases/conditions that benefit from increased angiogenesis can be treated with the placenta-derived adherent cell exosomes and compositions described herein included, without limitation, myocardial infarction, congestive heart failure, peripheral artery disease, critical limb ischemia, peripheral vascular disease, hypoplastic left heart syndrome, diabetic foot ulcer, venous ulcer, or arterial ulcer.
  • kits for treating a subject having a disruption of blood flow comprising
  • the methods provided herein comprise treating a subject having ischemia with the placenta-derived adherent cell exosomes provided herein, or a composition thereof.
  • the ischemia is peripheral arterial disease (PAD), e.g., is critical limb ischemia (CLI).
  • the ischemia is peripheral vascular disease (PVD), peripheral arterial disease, ischemic vascular disease, ischemic heart disease, or ischemic renal disease.
  • the placenta-derived adherent cell exosomes described herein are administered to a subject in need of therapy for any of the diseases or conditions described herein (see Section 5.4.1).
  • a composition described herein is administered to a subject in need of therapy for any of the diseases or conditions described herein.
  • said subject is a human.
  • compositions described herein are administered to a subject ⁇ e.g., a human) in need of a therapy to increase angiogensis and/or vascularization.
  • a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions described herein, i.e., compositions comprising the placenta-derived adherent cell exosomes described herein.
  • Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.
  • kits described herein can be used in the above methods (see Section 5.4).
  • the compositions described herein can be prepared in a form that is easily administrable to an individual.
  • the composition can be contained within a container that is suitable for medical use.
  • a container can be, for example, a sterile plastic bag, flask, jar, or other container from which the compositions can be easily dispensed.
  • the container can be a blood bag or other plastic, medically-acceptable bag suitable for the intravenous administration of a liquid to a recipient.
  • the placenta-derived adherent cell exosomes described herein, and compositions thereof can be loaded with agent(s), e.g., pharmaceutical agent(s), exogenous to the exosomes.
  • agent(s) e.g., pharmaceutical agent(s)
  • exosomes and compositions thereof can, for example, be taken up into target cells, e.g., cells other than the cell type from which the exosomes were obtained, and thereby deliver the exogenous agent(s), e.g., pharmaceutical agent(s), into the target cells.
  • such a method comprises incubating a placenta-derived adherent cell exosome and an exogenous agent, e.g. , pharmaceutical agent, for example incubating at room temperature, with or without saponin permeabilization, freeze/thaw cycles, sonication, or extrusion. See, e.g., Haney et ah, 2015, J. Controlled Release 207: 18-30, which is incorporated herein by reference.
  • the exogenous agent e.g.
  • incubation e.g., incubation at room temperature, is performed without saponin permeabilization of the placenta-derived adherent cell exosome.
  • incubation e.g., incubation at room temperature
  • incubation at room temperature is performed with saponin permeabilization of the placenta-derived adherent cell exosome.
  • the exogenous agent e.g. , pharmaceutical agent
  • the exogenous agent is loaded into the placenta-derived adherent cell exosome by freeze/thaw cycles, for example, 1, 2, 3, 4, 5, or more freeze/thaw cycles.
  • the exogenous agent, e.g., pharmaceutical agent is loaded into the placenta- derived adherent cell exosome by sonication.
  • the exogenous agent e.g.
  • pharmaceutical agent is loaded into the placenta-derived adherent cell exosome by extrusion.
  • the exogenous agent e.g., pharmaceutical agent
  • methods of loading exosomes with exogenous agents, for example, pharmaceutical agents comprise any combination of the above.
  • the exogenous agent, e.g., pharmaceutical agent, incorporated into the placenta-derived adherent cell placenta-derived adherent cell exosomes described herein comprises a polypeptide.
  • the exogenous agent, e.g., pharmaceutical agent is a binding agent, for example, an antibody, such as, e.g., a human, humanized, or chimeric antibody, or antigen-binding fragment thereof.
  • the antibody is a monospecific, bispecific or multispecific antibody, or antigen-binding fragment thereof.
  • the antibody or antigen binding fragment thereof is a single- chain antibody or a Fab fragment.
  • the antibody or antigen-binding fragment thereof would not internalize into a target cell without the aid of the placenta-derived adherent cell exosome.
  • the exogenous agent, e.g., pharmaceutical agent, loaded into the placenta-derived adherent cell exosomes described herein comprises one or more nucleic acids.
  • the one or more nucleic acids comprise a siR A or an miR A.
  • the exogenous agent, e.g., pharmaceutical agent, loaded into the placenta-derived adherent cell exosomes described herein comprises one or more gene- modifying components.
  • the one or more gene -modifying components comprise a CRISPR-Cas system.
  • the CRISPR-Cas system comprises a guide RNA.
  • the CRISPR-Cas system comprises an endonuclease.
  • the CRISPR-Cas system comprises a guide RNA and an endonuclease.
  • the CRISPR-Cas system comprises Cas9.
  • the CRISPR-Cas system comprises Cpfl .
  • the one or more gene-modifying components comprise a zinc finger nuclease.
  • the one or more gene-modifying components comprise a transcription activator-like effector nuclease (TALEN) system.
  • an exogenous agent e.g., a pharmaceutical agent
  • the exogenous agent is loaded into a placenta-derived adherent cell exosome.
  • the target cell is a cell other than the cell type from which the exosome was obtained.
  • the exogenous agent, e.g. , pharmaceutical agent, loaded into the placenta-derived adherent cell exosomes described herein comprises a polypeptide.
  • the exogenous agent e.g., pharmaceutical agent is a binding agent, for example, an antibody, such as, e.g., a human, humanized, or chimeric antibody, or antigen-binding fragment thereof.
  • a binding agent for example, an antibody, such as, e.g., a human, humanized, or chimeric antibody, or antigen-binding fragment thereof.
  • the antibody is a monospecific, bispecific or multispecific antibody, or antigen- binding fragment thereof.
  • the antibody or antigen binding fragment thereof is a single-chain antibody or a Fab fragment.
  • the antibody or antigen-binding fragment thereof would not internalize into a target cell, e.g. , a cell other than the cell type from which the exosomes were obtained, without the aid of the placenta- derived adherent cell exosome.
  • the exogenous agent e.g.,
  • the pharmaceutical agent, loaded into the placenta-derived adherent cell exosomes described herein comprises one or more nucleic acids.
  • the one or more nucleic acids comprise a siRNA.
  • the exogenous agent, e.g., pharmaceutical agent, loaded into the placenta-derived adherent cell exosomes described herein comprises one or more gene -modifying components.
  • the one or more gene-modifying components comprise a CRISPR-Cas system.
  • the CRISPR-Cas system comprises a guide RNA.
  • the CRISPR-Cas system comprises an endonuclease.
  • the CRISPR-Cas system comprises a guide RNA and an endonuclease. In more specific embodiments, the CRISPR-Cas system comprises Cas9. In more specific embodiments, the CRISPR-Cas system comprises Cpfl . In specific embodiments, the one or more gene-modifying components comprise a zinc finger nuclease. In specific embodiments, the one or more gene -modifying components comprise a transcription activator-like effector nuclease (TALEN) system.
  • TALEN transcription activator-like effector nuclease
  • the exogenous agent e.g., pharmaceutical agent
  • the exogenous agent comprises a polypeptide.
  • the exogenous agent, e.g., pharmaceutical agent is a binding agent, for example, an antibody, such as, e.g., a human, humanized, or chimeric antibody, or antigen-binding fragment thereof.
  • the antibody is a monospecific, bispecific or multispecific antibody, or antigen-binding fragment thereof.
  • the antibody or antigen binding fragment thereof is a single- chain antibody or a Fab fragment.
  • the antibody or antigen-binding fragment thereof would not internalize into a target cell without the aid of the placenta-derived adherent cell exosome.
  • the exogenous agent, e.g., pharmaceutical agent, loaded into the placenta-derived adherent cell exosomes described herein comprises one or more nucleic acids.
  • the one or more nucleic acids comprise an siRNA or an miRNA.
  • the exogenous agent, e.g., pharmaceutical agent, loaded into the placenta-derived adherent cell exosomes described herein comprises one or more gene -modifying components.
  • the one or more gene-modifying components comprise a CRISPR-Cas system.
  • the CRISPR-Cas system comprises a guide RNA.
  • the CRISPR-Cas system comprises an endonuclease. In more specific embodiments, the CRISPR-Cas system comprises a guide RNA and an endonuclease. In more specific embodiments, the CRISPR-Cas system comprises Cas9. In more specific embodiments, the CRISPR-Cas system comprises Cpfl . In specific embodiments, the one or more gene-modifying components comprise a zinc finger nuclease. In specific embodiments, the one or more gene -modifying components comprise a transcription activator-like effector nuclease (TALEN) system.
  • TALEN transcription activator-like effector nuclease
  • compositions comprising placenta-derived adherent cell exosomes loaded with one or more exogenous agents, for example, pharmaceutical agents.
  • the exogenous agent e.g., pharmaceutical agent
  • incorporated into the placenta-derived adherent cell exosomes described herein comprises a polypeptide.
  • the exogenous agent, e.g., pharmaceutical agent is a binding agent, for example, an antibody, such as, e.g., a human, humanized, or chimeric antibody, or antigen-binding fragment thereof.
  • the antibody is a monospecific, bispecific or multispecific antibody, or antigen-binding fragment thereof.
  • the antibody or antigen binding fragment thereof is a single-chain antibody or a Fab fragment.
  • the antibody or antigen-binding fragment thereof would not internalize into a target cell without the aid of the placenta-derived adherent cell exosome.
  • the exogenous agent e.g., pharmaceutical agent
  • loaded into the placenta- derived adherent cell exosomes described herein comprises one or more nucleic acids.
  • the one or more nucleic acids comprise an siR A or an miRNA.
  • the exogenous agent, e.g., pharmaceutical agent, loaded into the placenta- derived adherent cell exosomes described herein comprises one or more gene-modifying components.
  • the one or more gene-modifying components comprise a CRISPR-Cas system.
  • the CRISPR-Cas system comprises a guide RNA.
  • the CRISPR-Cas system comprises an endonuclease.
  • the CRISPR-Cas system comprises a guide RNA and an
  • the CRISPR-Cas system comprises Cas9. In more specific embodiments, the CRISPR-Cas system comprises Cpf 1.
  • the one or more gene-modifying components comprise a zinc finger nuclease. In specific embodiments, the one or more gene -modifying components comprise a transcription activatorlike effector nuclease (TALEN) system.
  • Placenta-derived adherent cell exosomes were isolated from CD 10 , CD200 , CD105 + , CD34 " placenta-derived adherent cell cultures according to the following methods:
  • Fetal bovine serum was depleted of contaminating bovine exosomes by ultracentrifugation at 10,000xg for 1 hour, then at 100,000xg for 18 hours at 4°C. The resulting supernatant was filtered through a 0.2 ⁇ filter prior to storage and use. Exosome-depleted FBS was mixed with Dulbecco's Modified Eagle's Medium (DMEM) for 24 hours to produce growth medium. Growth medium was warmed to 37°C and placenta-derived adherent cells were plated at a density of 300-1,000 cells/cm 2 and cultured for 3 days or until 80% confluent in a cell culture platform device (Corning CELLSTACK 10-Tray with CELLBIND coating).
  • DMEM Dulbecco's Modified Eagle's Medium
  • Placenta- derived adherent cell exosomes were plated at passage six, and culture supernatant was collected at passage seven.
  • the placental source of the placenta-derived adherent cells used to isolate the exosomes described herein did not include chorionic villi, thus the placenta-derived adherent cells used to produce placenta-derived adherent cell exosomes did not include chorionic villi mesenchymal stem cells.
  • the cell culture monolayer was washed with PBS and replenished with serum-free medium (DMEM and lx glutamine). After 48 hours, the serum-free culture supernatant was collected and subjected to exosome enrichment and isolation procedure as described below. The resulting cell monolayer was harvested for cell count, exosome yield comparison and comparison studies.
  • serum-free medium DMEM and lx glutamine
  • the isolated exosome compositions were aliquoted in 2 mL cryo vials and stored at - 20 to -80°C.
  • Placenta-derived adherent cell exosomes were isolated as in Section 6.1. Four hundred micrograms of isolated material was analyzed using Exo-CheckTM exosome antibody array (System Biosciences) according to the manufacturer's protocol. Exosome lysates were incubated overnight on the antibody array and the sample was imaged using a Kodak Gel-Logic system and developed after a 2 minute luminescence exposure. As shown in Figure 1 (bottom) placenta-derived adherent cell exosome material resulted in detectable signal for the four markers FLOT-1, ALIX, ANXA5 and TSGIOI . The use of a positive control sample, included as part of the array kit, resulted in a detectable signal for these markers as well ( Figure 1 top).
  • Isolated exosomes were negative stained and imaged using transmission electron microscopy (TEM) ( Figure 2 A) and were found to exist as discrete bodies -lOOnm in diameter, often in a cup-like shape (arrows), both characteristics of exosomes.
  • the purified exosomes were further analyzed by nanoparticle tracking analysis (NT A) to determine the size distribution of the isolated population.
  • NT A nanoparticle tracking analysis
  • placenta-derived adherent cell exosomes were an average size of 139nm, consistent with the known size of exosomes isolated from other cell types.
  • Placenta-derived adherent cell exosomes were isolated as in Section 6.1 and further analyzed by size-exclusion high-performance liquid chromatography (SE-HPLC). Elution profiles of exosomes from chorionic villi mesenchymal stem cells (MSCs) were compared to exosomes obtained from serum-containing ("Growth Supernatant") and serum-free ("Serum Free Supernatant) placenta-derived adherent cell cultures. Elution profiles of exosome preparations ( Figures 3B-D, arrows) were analyzed in comparison to the elution peaks of known culture medium contaminants ( Figure 3 A).
  • Chorionic villi MSC exosomes contained detectable levels of the contaminants Thyroglobulin and BSA ( Figure 3B).
  • Growth Supernatant placenta-derived adherent cell exosomes also contained detectable levels of Thyroglobulin and BSA ( Figure 3C), while Serum Free Supernatant placenta-derived adherent cell exosomes contained no detectable levels of any of such contaminants ( Figure 3D).
  • Elution profiles of exosomes isolated from either Growth Supernatant or Serum Free cultures were characterized by a peak consistent with that of the positive control exosomes.
  • FACS Fluorescence Activated Cell Sorting
  • exosomes may contain small nucleic acids, including miRNAs.
  • the composition of miRNAs contained within exosomes may vary between cell types from which exosomes were derived, and the presence and abundance of miRNAs can be determined by methods known in the art, including real-time PCR (RT-PCR).
  • RT-PCR real-time PCR
  • Placenta-derived adherent cell exosomes isolated as in Section 6.1 were analyzed by FACS, and the composition of surface markers was compared to exosomes isolated from either chorionic villi MSCs or pre-adipocyte MSCs. The exosomes from these three cell types were determined to differentially contain several surface markers (Table 1). Using FACS analysis, exosomes from placenta-derived adherent cells were found to contain a number of markers unique or enriched in these exosomes as compared to exosomes from chorionic villi MSCs or pre-adipocyte MSCs.
  • placenta-derived adherent cell exosomes contained CD10 and CD55, both of which were absent in both mesenchymal stem cell exosome populations. Placenta-derived adherent cell exosomes also contained a higher level of CD49c, CD82, CD90, and CD 142, e.g., a 0.5 to 1 log higher level, as compared to the two mesenchymal stem cell exosome populations (Table 1).
  • the placenta-derived adherent cell exosomes contained a lower level of CD 164, e.g., a 0.5 to 1 log lower level, as compared to the two mesenchymal stem cell exosome populations (Table 1).
  • Placenta-derived mesenchymal stem cell exosomes also contained detectable levels of CD295, which was not detected on pre-adipocyte MSC exosomes (not shown). As shown in Table 1 , the number of "+" symbols in each entry is correlated with the level of the indicated markers, whereas "-" symbols represent no detectable levels of the indicated marker.
  • Table 1 Surface antigens of placenta-derived adherent cell exosomes compared to pre- adipocyte MSC exosomes and chorionic villi MSC exosomes
  • Placenta-derived adherent cell exosomes and chorionic villi mesenchymal stem cell exosomes differ in their miRNA content
  • Placenta-derived adherent cell exosomes were isolated using the Exoquick precipitation method according to the manufacturer's protocol (System Biosciences). Culture supernatant was centrifuged for 15 minutes at 3000 x g, and the resulting pellet was discarded. Two milliliters of the resulting supernatant was added to 10ml tissue culture supernatant and mixed by inversion. The resulting mixture was incubated at 4°C overnight.
  • the mixture was centrifuged at 1500 x g for 30 minutes, the supernatant was discarded and the pellet was isolated. The remaining liquid was removed by aspiration after centrifuging for additional 5 minutes at 1500 x g. The pellet was reconstituted in 200ul PBS.
  • placenta-derived adherent cell exosomes contain higher levels of all miRNAs analyzed in each of the three groups as compared to chorionic villi MSCs. These data further indicate that the placenta-derived adherent cell exosomes described herein are distinct from chorionic villi mesenchymal stem cell exosomes on the basis of miRNA content.
  • Table 2 Ct values of miRNAs from placenta-derived adherent cell exosomes and chorionic villi mesenchymal stem cell exosomes. Chorionic Villi
  • miR-451 26.906 37.331 10.425 miR-142-3p 30.405 38.031 7.626 miR-16-5p 20.264 26.87 6.606 miR-296-5p 25.017 30.786 5.769 miR-223-3p 27.951 33.437 5.486 miR-92 19.689 24.958 5.269
  • Placenta-derived adherent cell exosomes contain angiogenic proteins
  • an Angioplex was performed using Human Mag Bead kit, HAGP1MAG-12K (Millipore). This kit contains analytes for detecting the following 17 cytokines: Leptin, Endoglin, Follistatin, HGF, Angiopoietin-2, G-CSF, FGF-1, FGF-2, VEGF-A, VEGF-C, VEGF-D, EGF, Endothelin-1, BMP-9, IL-8, HB-EGF, and PLGF. Exosomes were analyzed according to the manufacturer's suggested protocol.
  • Placenta-derived adherent cell exosomes displayed detectable levels of several cytokines including HGF and VEGF-A (Figure 4B), Endoglin and Leptin ( Figure 4C), Angiopoietin-2, G-CSF, Follistatin, FGF-2, and IL-8 (not shown). Nearly all of these cytokines were present at a lower level in all growth media tested, indicating that the cytokine levels are specifically associated with the exosomes. These data indicate that placenta-derived adherent cell exosomes contain protein factors that are known to promote angiogenesis.
  • exosomal uptake assays were performed using blood obtained in TruCulture tubes. Isolated placenta-derived adherent cell exosomes (see Section 6.1) were labeled with 2 ⁇ of the fluorophore PKH26 by adding 2 ⁇ 1 PKH26 to 1ml exosome suspension and incubated for 5 minutes at room temperature in the dark. Exosomes were recovered using a Centricon lOkDa molecular weight cutoff column according to the
  • HUVECs Human Vascular Endothelial Cells
  • placenta-derived adherent cells and placenta-derived adherent cell exosomes reduce the levels of specific cytokines in a dose-dependent manner.
  • the proinflammatory cytokines TNF-a, IL-12p40, MlPlb and IL-1B were all reduced when incubated with increasing amounts of placenta-derived adherent cells or placenta-derived adherent cell exosomes in LPS-stimulated whole blood.
  • MCP1 levels were increased by both placenta-derived adherent cells and placenta-derived adherent cell exosomes in stimulated whole blood, indicating that placenta-derived adherent cells and placenta-derived adherent cell exosomes can affect cytokine production in cultured cells.
  • placenta-derived adherent cell exosomes do not enhance the levels of specific cytokines that are enhanced in the presence of placenta-derived adherent cells.
  • IFN- ⁇ , IL-6, IL-8 and GM-CSF, cytokines associated with inflammation were not enhanced in the presence of placenta-derived adherent cell exosomes in stimulated whole blood. This finding indicates that placenta-derived adherent cell exosomes exert a differential effect on cultured blood than that of cells from which they were derived.
  • HUVECs Human vascular endothelial cells at passage 3 or 4 were plated in 48-well microtiter dishes at a density of 28,000 cells per well. Cells were maintained in 0.5mL of either PBD or EBM-2 culture medium (Lonza) on GRF-Matrigel for 3 days. HUVECs were then incubated with different concentrations of placenta-derived adherent cell exosomes isolated from either serum-containing ("growth exosomes") or serum-free (“SF exosomes”) placenta-derived adherent cell cultures. HUVEC growth patterns, including node formation and tube segment length (surrogates for angiogenic potential) were monitored every two hours for 18-19 hours total. HUVEC growth parameters were determined using IncuCyte live cell imaging system (Essen Bioscience) and quantified using ImageJ.
  • growth exosomes increased tube segment length and branch point frequency in cultured HUVECs in a dose-dependent manner.
  • isolated purified exosomes in concentrations ranging from 5 ⁇ g/well to 10( ⁇ g/well increased tube segment length (8A, left).
  • the HUVECs treated with growth exosomes had a higher number of nodes as compared to HUVECs treated with PBS (8A, right).
  • placenta-derived adherent cell exosomes isolated from serum-free cultures increased HUVEC tube segment length and branch point frequency.
  • HUVECs cultured in the presence of exosomes ranging in concentration of 5 ⁇ g/well to 10( ⁇ g/well increased tube segment length (8B, left) and branch point frequency (8B, right) as compared to HUVECs cultured in the presence of PBS.
  • HUVEC cells (Lonza Lot 8F3265; 032514AR) were expanded to passage 4 in complete EGM-2 Media. The cells were harvested, seeded on fibronectin coated plates at high density, and allow to attach for 3 hours until -100% confluent. Cells were cultured in the absence of serum ⁇ 2 hours in EBM-2 medium. Cultured HUVECs were incubated with placenta-derived adherent cell culture supernatant, 50 ⁇ g of placenta-derived adherent cell exosomes, or culture medium as a control. HUVEC supernatant and cell lysates were collected at 4, 24, and 48 hours, and gene expression was analyzed at these early, intermediate, and late time points.
  • VEGF pathway array results are shown in Figure 8C (darker shades indicate higher expression level).
  • HUVECs failed to express ACTA1, BAD, CASP9, MAP2K1, PLCG1, and SHC1 under any conditions, but 26/44 VEGF Pathway genes were up- regulated in HUVECs treated with placenta-derived adherent cell exosomes and/or placenta- derived adherent cell culture supernatant (Figure 8C).
  • VEGF Pathway genes were up- regulated in HUVECs treated with placenta-derived adherent cell exosomes and/or placenta- derived adherent cell culture supernatant (Figure 8C).
  • many of these genes are known to play an important role in angiogenesis.
  • Isolated monocytes were cultured in the presence of GM-CSF for 7-10 days until differentiated into macrophages. 5xl0 4 macrophages were co-cultured with placenta-derived adherent cell exosomes or placenta-derived adherent cells and lOOng/mL LPS for 22-24hrs. Secreted cytokines were profiled using a human immune multiplex panel (Millipore, HCYTO- MAG-60K). Assays were performed according to manufacturer's protocol using a Luminex FlexMAP-3D system.
  • placenta-derived adherent cells and placenta-derived adherent cell exosomes altered the levels of specific cytokines produced by monocyte-derived
  • TNF-a and MCP-1 were both reduced when incubated with increasing amounts placenta-derived adherent cell exosomes in the presence of LPS-stimulated macrophages. Placenta-derived adherent cells did not reduce the levels of MCP-1 in macrophage cultures.
  • placenta-derived adherent cell exosomes and placenta-derived adherent cells both suppressed TNF-a secretion in cultured macrophages, while placenta-derived adherent cell exosomes but not placenta-derived adherent cells broadly suppressed cytokine secretion (e.g., IL-8 secretion) in cultured macrophages. Notably, this is in contrast to the changes in cytokine expression observed in whole blood, (see Example 7).
  • cytokine secretion e.g., IL-8 secretion
  • placenta-derived adherent cell exosomes can alter cytokine expression in cultured immune cells in a manner distinct from the cells from which the exosomes were derived.
  • monocyte-derived macrophages are incubated with lysed placenta-derived adherent cell exosomes
  • IL-8 suppression is attenuated when compared to cultures incubated with intact placenta-derived adherent cell exosomes ( Figure 9B, right).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PCT/US2015/054629 2014-10-09 2015-10-08 Placenta-derived adherent cell exosomes and uses thereof Ceased WO2016057755A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
EP15849339.5A EP3204022B1 (en) 2014-10-09 2015-10-08 Placenta-derived adherent cell exosomes and uses thereof
AU2015330855A AU2015330855A1 (en) 2014-10-09 2015-10-08 Placenta-derived adherent cell exosomes and uses thereof
CN202310711769.3A CN116731958A (zh) 2014-10-09 2015-10-08 胎盘来源的贴壁细胞外泌体及其用途
CA2964114A CA2964114A1 (en) 2014-10-09 2015-10-08 Placenta-derived adherent cell exosomes and uses thereof
US15/517,438 US20170252379A1 (en) 2014-10-09 2015-10-08 Placenta-derived adherent cell exosomes and uses thereof
DK15849339.5T DK3204022T3 (da) 2014-10-09 2015-10-08 Placenta-afledte adhærente celle-exosomer og anvendelser deraf
CN201580054280.7A CN107106615A (zh) 2014-10-09 2015-10-08 胎盘来源的贴壁细胞外泌体及其用途
JP2017518955A JP2017536096A (ja) 2014-10-09 2015-10-08 胎盤由来の接着細胞エクソソームおよびそれらの使用
US16/740,054 US11173182B1 (en) 2014-10-09 2020-01-10 Placenta-derived adherent cell exosomes and uses thereof
AU2021204332A AU2021204332A1 (en) 2014-10-09 2021-06-25 Placenta-derived adherent cell exosomes and uses thereof
US17/495,985 US20220241347A1 (en) 2014-10-09 2021-10-07 Placenta-derived adherent cell exosomes and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462062046P 2014-10-09 2014-10-09
US62/062,046 2014-10-09

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US15/517,438 A-371-Of-International US20170252379A1 (en) 2014-10-09 2015-10-08 Placenta-derived adherent cell exosomes and uses thereof
US16/740,054 Continuation US11173182B1 (en) 2014-10-09 2020-01-10 Placenta-derived adherent cell exosomes and uses thereof

Publications (1)

Publication Number Publication Date
WO2016057755A1 true WO2016057755A1 (en) 2016-04-14

Family

ID=55653751

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/054629 Ceased WO2016057755A1 (en) 2014-10-09 2015-10-08 Placenta-derived adherent cell exosomes and uses thereof

Country Status (8)

Country Link
US (3) US20170252379A1 (enExample)
EP (1) EP3204022B1 (enExample)
JP (3) JP2017536096A (enExample)
CN (2) CN116731958A (enExample)
AU (2) AU2015330855A1 (enExample)
CA (1) CA2964114A1 (enExample)
DK (1) DK3204022T3 (enExample)
WO (1) WO2016057755A1 (enExample)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018208702A1 (en) * 2017-05-09 2018-11-15 Saint Louis University Treatment of cancer and infectious diseases with natural killer (nk) cell-derived exosomes
US10195290B1 (en) 2017-08-25 2019-02-05 Codiak Biosciences, Inc. Preparation of therapeutic exosomes using membrane proteins
CN109477072A (zh) * 2016-05-16 2019-03-15 埃克森蒂姆生物技术公司 间充质干细胞及其用于治疗肌肉损伤和肌肉相关疾病的用途
WO2019088478A1 (ko) * 2017-10-31 2019-05-09 (주)아모레퍼시픽 유산균 유래의 세포밖 베지클을 포함하는 면역조절용 조성물
WO2019092287A1 (en) * 2017-11-13 2019-05-16 Evox Therapeutics Ltd Protein engineered extracellular vesicles
WO2019099955A1 (en) * 2017-11-16 2019-05-23 Celularity, Inc. Cultivation of placenta to isolate exosomes
US10337001B2 (en) 2014-12-03 2019-07-02 Agilent Technologies, Inc. Guide RNA with chemical modifications
JP2020521821A (ja) * 2017-06-02 2020-07-27 エクソレンス、バイオテクノロジーＥｘｏｌｌｅｎｃｅ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ 体外衝撃波を用いた細胞外小胞体内へ標的物質を伝達する方法
US10723782B2 (en) 2017-12-28 2020-07-28 Codiak Biosciences, Inc. Exosomes for immuno-oncology and anti-inflammatory therapy
US10767175B2 (en) 2016-06-08 2020-09-08 Agilent Technologies, Inc. High specificity genome editing using chemically modified guide RNAs
US10959952B2 (en) 2015-06-10 2021-03-30 Board Of Regents, The University Of Texas System Use of exosomes for the treatment of disease
EP3630947A4 (en) * 2017-05-24 2021-04-07 Nanosomix Inc. DETECTION OF BIOMARKERS ON VESICLES FOR THE DIAGNOSIS AND PROGNOSIS OF DISEASES AND DISORDERS
EP3624817A4 (en) * 2017-05-16 2021-05-19 Exostem Biotec Ltd. METHODS OF INHIBITING AGING AND TREATING AGING-RELATED DISORDERS
US11306309B2 (en) 2015-04-06 2022-04-19 The Board Of Trustees Of The Leland Stanford Junior University Chemically modified guide RNAs for CRISPR/CAS-mediated gene regulation
US11576872B2 (en) 2017-05-08 2023-02-14 Flagship Pioneering Innovations V, Inc. Compositions for facilitating membrane fusion and uses thereof
US11884915B2 (en) 2021-09-10 2024-01-30 Agilent Technologies, Inc. Guide RNAs with chemical modification for prime editing

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200098600A (ko) 2017-12-14 2020-08-20 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 정제된 엑소좀 생성물, 제조 방법 및 사용 방법
US20210038652A1 (en) * 2018-01-30 2021-02-11 Histogen, Inc. Extracellular vesicles derived from cells cultured under hypoxic conditions and uses thereof
JP6825182B2 (ja) * 2018-06-19 2021-02-03 フーワイ ホスピタル， チャイニーズ アカデミー オブ メディカル サイエンシズ アンド ペキン ユニオン メディカル カレッジ 薬剤前処理による間葉系幹細胞由来エクソソームの調製方法
WO2020023594A1 (en) * 2018-07-24 2020-01-30 Mayo Foundation For Medical Education And Research Compositions and methods involving transforming extracellular vesicles
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN109554341B (zh) * 2018-12-18 2021-11-19 深圳先进技术研究院 无创超声处理细胞在制备外泌体中的应用、外泌体及其制备方法和应用
CN110093274B (zh) * 2019-05-13 2020-08-11 山东大学 一种增加细胞产生的细胞外囊泡数量的挤压装置及其应用
PH12021553167A1 (en) * 2019-06-19 2022-08-15 Celularity Inc Exosomes for disease treatment
WO2021210852A1 (ko) * 2020-04-14 2021-10-21 (주)녹십자웰빙 태반 유래 물질을 포함하는 항바이러스 조성물
KR20220030552A (ko) * 2020-09-03 2022-03-11 (주)녹십자웰빙 태반 유래 엑소좀을 포함하는 간세포 증식 또는 항염증 효능 조성물
WO2024102969A1 (en) * 2022-11-10 2024-05-16 Board Of Regents, The University Of Texas System Use of fecal derivatives and fecal derived extracellular vesicles to enhance immunity

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120202209A1 (en) * 2009-09-22 2012-08-09 Centre National De La Recherche Scientifique - Cnrs Cell imaging method for viewing microrna biogenesis in the cells
CA2860144A1 (en) * 2011-12-22 2013-06-27 Takahiro Ochiya Method of exosome analysis, reagent for exosome analysis, and analyzer for exosome
US20130195899A1 (en) * 2012-01-31 2013-08-01 Medistem, Inc. Therapeutic immune modulation by stem cell secreted exosomes
US20130245103A1 (en) * 2011-03-31 2013-09-19 modeRNA Therapeutics Modified polynucleotides for the production of factor ix
US20130337558A1 (en) * 2008-09-02 2013-12-19 Pluristem Ltd. Adherent cells from placenta tissue and use thereof in therapy
WO2014022852A1 (en) * 2012-08-03 2014-02-06 Aptamir Therapeutics, Inc. Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders
US20140179770A1 (en) * 2012-12-12 2014-06-26 Massachusetts Institute Of Technology Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
WO2014100434A1 (en) * 2012-12-19 2014-06-26 Caris Science, Inc. Compositions and methods for aptamer screening
US20140220580A1 (en) * 2011-06-16 2014-08-07 Kirk Brown Biomarker compositions and methods
WO2014145075A2 (en) * 2013-03-15 2014-09-18 The Trustees Of Princeton University Methods and devices for high throughpout purification

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2336300B1 (en) 2001-02-14 2015-07-08 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
KR20200123283A (ko) 2005-12-29 2020-10-28 안트로제네시스 코포레이션 태반 줄기 세포 집단
KR20210149904A (ko) 2008-08-20 2021-12-09 안트로제네시스 코포레이션 단리된 태반 세포를 사용한 뇌졸중 치료
CN102301002A (zh) * 2008-11-12 2011-12-28 卡里斯生命科学卢森堡控股有限责任公司 使用外来体来确定表现型的方法和系统
AU2011237747B2 (en) * 2010-04-07 2015-07-23 Celularity Inc. Angiogenesis using placental stem cells
JP6433896B2 (ja) * 2012-08-13 2018-12-05 シーダーズ−サイナイ・メディカル・センターＣｅｄａｒｓ−Ｓｉｎａｉ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ 組織再生のためのエキソソームおよびマイクロリボ核酸

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130337558A1 (en) * 2008-09-02 2013-12-19 Pluristem Ltd. Adherent cells from placenta tissue and use thereof in therapy
US20120202209A1 (en) * 2009-09-22 2012-08-09 Centre National De La Recherche Scientifique - Cnrs Cell imaging method for viewing microrna biogenesis in the cells
US20130245103A1 (en) * 2011-03-31 2013-09-19 modeRNA Therapeutics Modified polynucleotides for the production of factor ix
US20140220580A1 (en) * 2011-06-16 2014-08-07 Kirk Brown Biomarker compositions and methods
CA2860144A1 (en) * 2011-12-22 2013-06-27 Takahiro Ochiya Method of exosome analysis, reagent for exosome analysis, and analyzer for exosome
US20130195899A1 (en) * 2012-01-31 2013-08-01 Medistem, Inc. Therapeutic immune modulation by stem cell secreted exosomes
WO2014022852A1 (en) * 2012-08-03 2014-02-06 Aptamir Therapeutics, Inc. Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders
US20140179770A1 (en) * 2012-12-12 2014-06-26 Massachusetts Institute Of Technology Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
WO2014100434A1 (en) * 2012-12-19 2014-06-26 Caris Science, Inc. Compositions and methods for aptamer screening
WO2014145075A2 (en) * 2013-03-15 2014-09-18 The Trustees Of Princeton University Methods and devices for high throughpout purification

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DING ET AL.: "Permanent Alteration of PCSK9 With In Vivo CRISPR-Cas9 Genome Editing", CIRC RES., vol. 115, 15 August 2014 (2014-08-15), pages 488 - 492, XP055428398 *
LAI ET AL.: "Proteolytic Potential of the MSC Exosome Proteome: Implications for an Exosome-Mediated Delivery of Therapeutic Proteasome", INTERNATIONAL JOURNAL OF PROTEOMICS, vol. 2012, 1 June 2012 (2012-06-01), XP055155534 *
VANDENBOORN ET AL.: "SiRNA delivery with exosome nanoparticles", NATURE BIOTECHNOLOGY, vol. 29, no. 4, 1 April 2011 (2011-04-01), pages 325 - 326, XP055428399 *

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10337001B2 (en) 2014-12-03 2019-07-02 Agilent Technologies, Inc. Guide RNA with chemical modifications
US10900034B2 (en) 2014-12-03 2021-01-26 Agilent Technologies, Inc. Guide RNA with chemical modifications
US11851652B2 (en) 2015-04-06 2023-12-26 The Board Of Trustees Of The Leland Stanford Junior Compositions comprising chemically modified guide RNAs for CRISPR/Cas-mediated editing of HBB
US11535846B2 (en) 2015-04-06 2022-12-27 The Board Of Trustees Of The Leland Stanford Junior University Chemically modified guide RNAS for CRISPR/Cas-mediated gene regulation
US11306309B2 (en) 2015-04-06 2022-04-19 The Board Of Trustees Of The Leland Stanford Junior University Chemically modified guide RNAs for CRISPR/CAS-mediated gene regulation
US10959952B2 (en) 2015-06-10 2021-03-30 Board Of Regents, The University Of Texas System Use of exosomes for the treatment of disease
US12150963B2 (en) 2016-05-16 2024-11-26 Exostem Biotec Ltd. Mesenchymal stem cell and use thereof for treatment of muscle injury and muscle-associated diseases
CN109477072A (zh) * 2016-05-16 2019-03-15 埃克森蒂姆生物技术公司 间充质干细胞及其用于治疗肌肉损伤和肌肉相关疾病的用途
EP3458574A4 (en) * 2016-05-16 2019-12-25 Exostem Biotec Ltd. MESENCHYMAL STEM CELL AND THE USE THEREOF FOR TREATING MUSCLE INJURIES AND MUSCLE-ASSOCIATED DISEASES
US10973857B2 (en) 2016-05-16 2021-04-13 Exostembiotec Ltd. Mesenchymal stem cell and use thereof for treatment of muscle injury and muscle-associated diseases
US10767175B2 (en) 2016-06-08 2020-09-08 Agilent Technologies, Inc. High specificity genome editing using chemically modified guide RNAs
US11576872B2 (en) 2017-05-08 2023-02-14 Flagship Pioneering Innovations V, Inc. Compositions for facilitating membrane fusion and uses thereof
WO2018208702A1 (en) * 2017-05-09 2018-11-15 Saint Louis University Treatment of cancer and infectious diseases with natural killer (nk) cell-derived exosomes
EP3624817A4 (en) * 2017-05-16 2021-05-19 Exostem Biotec Ltd. METHODS OF INHIBITING AGING AND TREATING AGING-RELATED DISORDERS
EP3630947A4 (en) * 2017-05-24 2021-04-07 Nanosomix Inc. DETECTION OF BIOMARKERS ON VESICLES FOR THE DIAGNOSIS AND PROGNOSIS OF DISEASES AND DISORDERS
JP2020521821A (ja) * 2017-06-02 2020-07-27 エクソレンス、バイオテクノロジーＥｘｏｌｌｅｎｃｅ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ 体外衝撃波を用いた細胞外小胞体内へ標的物質を伝達する方法
US12257313B2 (en) 2017-08-25 2025-03-25 Lonza Sales Ag Preparation of therapeutic exosomes using membrane proteins
US10195290B1 (en) 2017-08-25 2019-02-05 Codiak Biosciences, Inc. Preparation of therapeutic exosomes using membrane proteins
US10561740B2 (en) 2017-08-25 2020-02-18 Codiak Biosciences, Inc. Preparation of therapeutic exosomes using membrane proteins
US11679164B2 (en) 2017-08-25 2023-06-20 Codiak Biosciences, Inc. Preparation of therapeutic exosomes using membrane proteins
WO2019088478A1 (ko) * 2017-10-31 2019-05-09 (주)아모레퍼시픽 유산균 유래의 세포밖 베지클을 포함하는 면역조절용 조성물
US11583560B2 (en) 2017-10-31 2023-02-21 Amorepacific Corporation Immunomodulatory composition comprising lactobacillus-derived extracellular vesicles
WO2019092287A1 (en) * 2017-11-13 2019-05-16 Evox Therapeutics Ltd Protein engineered extracellular vesicles
JP2021502105A (ja) * 2017-11-13 2021-01-28 エヴォックス・セラピューティクス・リミテッド タンパク質操作された細胞外小胞
WO2019099955A1 (en) * 2017-11-16 2019-05-23 Celularity, Inc. Cultivation of placenta to isolate exosomes
CN111433352A (zh) * 2017-11-16 2020-07-17 细胞结构公司 用以分离外泌体的胎盘培养
US10723782B2 (en) 2017-12-28 2020-07-28 Codiak Biosciences, Inc. Exosomes for immuno-oncology and anti-inflammatory therapy
US12030924B2 (en) 2017-12-28 2024-07-09 Lonza Sales Ag Exosomes for immuno-oncology and anti-inflammatory therapy
US12331100B2 (en) 2017-12-28 2025-06-17 Lonza Sales Ag Exosomes for immuno-oncology and anti-inflammatory therapy
US11884915B2 (en) 2021-09-10 2024-01-30 Agilent Technologies, Inc. Guide RNAs with chemical modification for prime editing

Also Published As

Publication number Publication date
CN116731958A (zh) 2023-09-12
CN107106615A (zh) 2017-08-29
US20170252379A1 (en) 2017-09-07
AU2021204332A1 (en) 2021-07-22
JP2023011580A (ja) 2023-01-24
CA2964114A1 (en) 2016-04-14
US11173182B1 (en) 2021-11-16
DK3204022T3 (da) 2021-03-08
US20220241347A1 (en) 2022-08-04
EP3204022A1 (en) 2017-08-16
JP2021040635A (ja) 2021-03-18
JP2017536096A (ja) 2017-12-07
EP3204022A4 (en) 2018-06-13
AU2015330855A1 (en) 2017-04-27
EP3204022B1 (en) 2020-12-02

Similar Documents

Publication Publication Date Title
US11173182B1 (en) Placenta-derived adherent cell exosomes and uses thereof
AU2021203382B2 (en) Therapeutic pooled blood apoptotic cell preparations and uses thereof
JP6716564B2 (ja) 安定したエクソソーム製剤の製造方法
US9877989B2 (en) Use of preparations comprising exosomes derived from mesenchymal stem cells (MSCs) in the prevention and therapy of inflammatory conditions
US20180221412A1 (en) Methods and compositions relating to mesenchymal stem cell exosomes
US20230181649A1 (en) Exosomes for disease treatment
JP2021503301A (ja) エキソソームを単離するための胎盤の培養
WO2023164241A1 (en) Method for enriching muse cells and obtaining exosomes, microvesicles or the secretome therefrom
WO2015076717A2 (en) Mscs in the treatment of cardiac disorders
US20220362341A1 (en) Treatment of major depressive disorder by low dose interleukin-2
US20230141224A1 (en) Fibroblast mediated expansion and augmentation of immune regulatory cells for treatment of acute respiratory distress syndrome (ards)
HK1242969A1 (en) Placenta-derived adherent cell exosomes and uses thereof
HK1242969B (en) Placenta-derived adherent cell exosomes and uses thereof
EP4123019A1 (en) Cord blood plasma-derived exosome or mimetic thereof and pharmaceutical use thereof
HK1241290A1 (en) Placenta-derived adherent cell exosomes and uses thereof
JP2024507587A (ja) 制御性Ｔ細胞（Ｔｒｅｇ）細胞外小胞組成物及び方法
US20230365930A1 (en) Immunological enhancement of stem cell activity in treatment of ovarian failure
JP2022551916A (ja) 新規調節性マクロファージ及びその使用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15849339

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2964114

Country of ref document: CA

Ref document number: 2017518955

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2015849339

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015849339

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2015330855

Country of ref document: AU

Date of ref document: 20151008

Kind code of ref document: A